Pathogenesis of Dry Eye in Graft Versus Host Disease (GVHD): Role of Ocular Mucins and Conjunctival Fibrosis by Shamloo, Kiumars
Chapman University 
Chapman University Digital Commons 
Pharmaceutical Sciences (PhD) Dissertations Dissertations and Theses 
Winter 5-2021 
Pathogenesis of Dry Eye in Graft Versus Host Disease (GVHD): 
Role of Ocular Mucins and Conjunctival Fibrosis 
Kiumars Shamloo 
Chapman University, shaml103@mail.chapman.edu 
Follow this and additional works at: https://digitalcommons.chapman.edu/
pharmaceutical_sciences_dissertations 
 Part of the Animal Experimentation and Research Commons, Eye Diseases Commons, and the 
Pharmacology Commons 
Recommended Citation 
Shamloo, K. Pathogenesis of Dry Eye in Graft Versus Host Disease (GVHD): Role of Ocular Mucins and 
Conjunctival Fibrosis. [dissertation]. Irvine, CA: Chapman University; 2021. https://doi.org/10.36837/
chapman.000230 
This Dissertation is brought to you for free and open access by the Dissertations and Theses at Chapman 
University Digital Commons. It has been accepted for inclusion in Pharmaceutical Sciences (PhD) Dissertations by 




PATHOGENESIS OF DRY EYE IN GRAFT VERSUS HOST DISEASE (GVHD): ROLE 
OF OCULAR MUCINS AND CONJUNCTIVAL FIBROSIS 





School of Pharmacy 
Submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy in Pharmaceutical Sciences 
May 2021 
 
Committee in charge: 
Ajay Sharma, Ph.D. Chair 
Keykavous Parang, Ph.D. 
Surya M. Nauli, Ph.D. 
Rennolds Ostrom, Ph.D. 
Jennifer Totonchy, Ph.D. 
Jason Yamaki, Pharm. D., Ph.D. 
 
 
The dissertation of Kiumars Shamloo is approved 
Ajay Sharma, Ph.D. Chair 
Keykavous Parang, Pharm.D., Ph.D. 
Surya M. Nauli, Ph.D. 
Rennolds Ostrom, Ph.D. 
Jennifer Totonchy, Ph.D. 
fo�mak1 (Mar 2, 202112:16 PST) 
Jason Yamaki, Pharm.D., Ph.D. 
January 2021
 III 
PATHOGENESIS OF DRY EYE IN GRAFT VERSUS HOST DISEASE (GVHD): ROLE 
OF OCULAR MUCINS AND CONJUNCTIVAL FIBROSIS 
Copyright © 2021 




























This dissertation would not have been possible without the inspiration and support of 
several wonderful individuals; my thanks and appreciation to all of them for being part of 
this journey and making this thesis possible. I owe my deepest gratitude to my supervisor 
Dr. Ajay Sharma for his instrumental role in shaping this project, his expertise, support, 
feedback, and time. With his consistent guidance, I have been successful in conducting 
this research and complete this dissertation. I am grateful to extend my thanks to other 
students Priya Mistry, Jacob Baker, Judy Weng, and laboratory technicians: Ashley 
Barbarino and Christopher Ross, for helping me around the projects. My sincere thanks 
also to my committee members: Dr. Surya Nauli, Dr. Keykavous Parang, Dr. Rennolds 
Ostrom, Dr. Jennifer Totonchi, Dr. Jason Yamaki, for their insightful comments and 
encouragement. Finally, my sincere gratitude to my family for their continuous and 
unparalleled love, help, and support. I am grateful to my wife for always being there for 
me as a friend. I am forever indebted to my sons Danny and Sam for their understanding 
and encouragement to finish this program. I appreciate their patience for all those years 
that I missed and didn’t spend enough time with them. Special thanks to all people who, 






LIST OF PUBLICATIONS: 
 
1. Alfuraih S, Barbarino A, Ross C, Shamloo K, Jhanji V, Zhang M, Sharma A. Effect of 
High Glucose on Ocular Surface Epithelial Cell Barrier and Tight Junction Proteins. 
Invest Ophthalmol Vis Sci. 2020; 61, 3. 
 
2. Mohieldin AM, Rajasekharreddy P, Sherpa RT, Alanazi M, Ashwaq, Alanazi A, 
Shamloo K, Ahsan A, AbouAlaiwi WA, Moresco JJ, Yates JR, Naul SM. Proteomic 
Identification Reveals the Role of Ciliary Extracellular-Like Vesicle in Cardiovascular 
Function. Adv. Sci. 2020; 1903140 
 
3. Shamloo K, Barbarino A, Alfuraih S, Sharma A. Graft Versus Host Disease-
Associated Dry Eye: Role of Ocular Surface Mucins and the Effect of Rebamipide, a 
Mucin Secretagogue. Invest Ophthalmol Vis Sci. 2019; 60: 4511-19 
 
4. Park SE, Shamloo K, Kristedja TA, Darwish S, Bisoffi M, Parang K, Tiwari RK. EDB-
FN Targeted Peptide-Drug Conjugates for Use against Prostate Cancer. Int J Mol Sci. 
2019; 20. pii: E3291. 
 
5. Pala R, Mohieldin AM, Sherpa RT, Kathem SH, Shamloo K, Luan Z, Zhou J, Zheng 
JG, Ahsan A, Nauli SM. Ciliotherapy: Remote Control of Primary Cilia Movement and 
Function by Magnetic Nanoparticles. ACS Nano. 2019; 13:3555-72 
 
6. Pala R, Mohieldin AM, Shamloo K, Sherpa RT, Kathem SH, Zhou J, Luan Z, Zheng 
JG, Ahsan A, Nauli SM. Personalized Nanotherapy by Specifically Targeting Cell 
Organelles to Improve Vascular Hypertension. Nano Lett. 2019;19: 904-14 
 
7. Amirrad F, Bousoik E, Shamloo K, Al-Shiyab H, Nguyen VV, Montazeri Aliabadi H. 
Alzheimer's Disease: Dawn of a New Era? J Pharm Pharm Sci. 2017; 20: 184-225. 
 
 VI 
8. Shamloo K, Chen J, Sardar J, Sherpa RT, Pala R, Atkinson KF, Pearce WJ, Zhang 
L, Nauli SM. Chronic Hypobaric Hypoxia Modulates Primary Cilia Differently in Adult 






























LIST OF CONFERENCE PRESENTATIONS: 
 
1. Shamloo K, Barbarino A, Alfuraih S, Sharma A. Role of mucins in the pathogenesis 
of dry eye associated with graft versus host disease (GVHD). Poster presented at 
Annual Meeting of Association for Research in Vision and Ophthalmology, Vancouver, 
British Columbia, Canada April 27-May 2 2019. 
 
2. Shamloo K, Alfuraih S, Barbarino A, Ross C, Sharma A. Effect of high glucose on the 
tight junction proteins of corneal and conjunctival epithelial cells. Poster accepted for 
presentation at 2020 annual meeting of Association for Research in Vision and 
ophthalmology at Baltimore, but the meeting was cancelled due to COVID-19 
 
3. Mistry P, Shamloo K, Ross C, Sharma A. Comparative analysis of hyperosmotic 
stress-mediated modulation of cytokine gene expression in human conjunctival and 
corneal epithelial cells. Poster accepted for presentation at 2020 annual meeting of 
Association for Research in Vision and ophthalmology at Baltimore, but the meeting 


















PATHOGENESIS OF DRY EYE IN GRAFT VERSUS HOST DISEASE (GVHD): ROLE 
OF OCULAR MUCINS AND CONJUNCTIVAL FIBROSIS 
by Kiumars Shamloo 
Allogenic hematopoietic stem cell transplantation is a procedure that offers a possible 
cure for hematologic cancers and other hematologic disorders. Unfortunately, despite the 
increasing survival rate of patients, the quality of their life is adversely affected by the 
allogeneic bone marrow transplantation’s major side effect i.e Graft vs. Host Disease 
(GVHD). GVHD is a complex, multi-organ disease resulting from an immunological attack 
by donor engrafted immune cells to host organs, including the eye surface. Mostly based 
on the time of disease onset after transplantation, GVHD is divided into the acute and 
chronic phase. The eyes may be involved in both acute and chronic GVHD, although 
ocular involvement is more common in the chronic GVHD with a more severe 
presentation. As high as 40%-60% of patients with chronic GVHD suffer from debilitating 
ocular surface damage manifesting as severe dry eye and cicatricial conjunctivitis. 
Several pathological mechanisms likely contribute to the etiology of ocular GVHD-
associated dry eye disease. Despite the high frequency of ocular surface involvement in 
patients experiencing GVHD, little is known about the underlying pathogenesis 
responsible for ocular GVHD-associated dry eye. In our first manuscript, using a mouse 
model of allogeneic transplantation, we demonstrated that ocular GVHD causes a 
decrease in tear film volume and corneal keratopathy. These ocular surfaces changes 
are accompanied by a significant decrease in the area and thickness of corneal 
glycocalyx, a decrease in ocular surface mucins, MUC4 and MUC5AC and loss of 
 IX 
conjunctival goblet cells. Our data showed that topical treatment by mucin secretagogue, 
rebamipide, partially attenuates GVHD-associated damage to ocular surface. 
Hyperosmolar tears are a consistent feature of dry eye disease. Our data demonstrated 
that hyperosmolar stress increases the gene expression of NFAT5, a tonicity-related 
transcription factor and pro-inflammatory cytokines (IL1, IL6, TNFα, IFN-γ) in human 
corneal and conjunctival epithelial cells. Next, we demonstrated that these 
proinflammatory cytokines differentially modulate the expression of MUC 1, and MUC 4 
in ocular surface epithelial cells, but they do not cause any notable change in glycocalyx 
or apoptotic cell death in stratified human corneal and conjunctival epithelial cells. 
Immune-mediated ocular surface damage in GVHD can initiate a wound healing response 
leading to fibrosis in the conjunctiva, a fibroblast-rich tissue. Conjunctival fibrosis may 
underlie the noted decrease in goblet cells and ocular surface mucins, thus contributing 
to GVHD-associated dry eye. Our results demonstrated that ocular GVHD causes a 
significant increase in expression of α-smooth muscle actin (SMA), a marker of 
myofibroblasts, in the conjunctiva. Immunostaining detected the presence of large 
number of myofibroblasts in bulbar orbital conjunctiva of GVHD mice. An increase in the 
components of renin-angiotensin system component (RAS), angiotensinogen and 
angiotensin converting enzyme, was also noted in the conjunctiva suggesting that ocular 
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Over the past few decades, allogeneic hematopoietic stem cell transplantation has 
emerged as a potentially curative therapy for some hematologic malignancies and 
hemoglobinopathies1. Despite the advances in HLA matching and the use of 
immunosuppressive drugs, graft versus host disease (GVHD) remains a frequent 
complication of allogeneic hematopoietic stem cell transplantation. GVHD is an immune 
condition caused by a complex interplay between donor immune cells, host immune 
organs, and host tissues 2-6. Depending upon the time of onset and clinical manifestations, 
GVHD is divided into the acute and chronic phases. Acute GVHD primarily affects the 
liver, skin, and intestine. On the other hand, chronic GVHD causes a high incidence of 
ocular complications 7-9.  
Ocular GVHD 
Ocular GVHD most often presents as severe dry eye and ocular surface disease, 
which can have a profound impact on the quality of life in its survivors 6. It is diagnosed 
based on eye-related signs and symptoms such as hyperemia, hemorrhagic 
conjunctivitis, pseudomembrane formation, lagophthalmos, pain, blurry vision, foreign 
body sensation, burning sensation, serious light sensitivity, acute conjunctivitis and 
corneal ulceration10.It happens in more than 60% of patients with chronic GVHD10. 
Without adequate treatment, dry eye disease in patients with GVHD may advance to 
corneal keratopathy, ulceration and lead to impairment of vision11. 
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Ocular surface mucins and glycocalyx 
Tear film is a thin layer of fluid that covers the eye surface. Normal tear film is critical for 
keeping the ocular surface hydrated and lubricated, thus preventing desiccation-induced 
damage to the ocular surface12. The lacrimal functional unit, including eye surface nerves, 
ocular surface glycocalyx, lacrimal glands, meibomian glands, and normal blinking 
response, all contribute collectively to a healthy tear film's secretion and maintenance12. 
The tear film, primarily made up of a muco-aqueous gel layer that underlies and partially 
mixes with an overlaying lipid layer, is critical for keeping the eye surface hydrated and 
lubricated 12. Tear film's mucous layer mainly consists of membrane-bound and secreted 
mucins. Mucins are high molecular weight glycoproteins made up of a protein core with 
extensive glycan N-acetyl galactosamine side chains13. Heavy glycosylation imparts a 
negative charge and hydrophilicity to the mucins14. These structural features account for 
their two vital physiological functions of repelling pathogens and keeping the eye surface 
hydrated and lubricated. The tear film mucins include the membrane-bound mucins 
(MUC): MUC1, MUC4, MUC16, soluble MUC7; it also includes the gel-forming secreted 
mucins MUC19, MUC5AC15. The membrane-bound mucins which are expressed on the 
apical surface of corneal and conjunctival epithelial cells, are glycosylated and sialylated 
along with galectin 3 form a continuous layer called glycocalyx. which help to protect cells 
against mechanical and chemical damage, prevent pathogen penetration into the eye, 
reduce friction during blinking, and maintain the hydrophilicity of the ocular surface. 
MUC5AC is mainly secreted by the goblet cells16. How GVHD affects ocular surface 
mucins and glycocalyx is not known 15.  
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Besides providing hydration, lubrication and antimicrobial functions, ocular surface 
membrane-tethered mucins have also been shown to act as signaling molecules. Specific 
localization of mucins to the apical surfaces of epithelial cells suggests that their signaling 
functions may be important as sensor mechanisms in response to invasion or damage of 
epithelia. MUC1 and MUC4 are the two membrane mucins, which have apparently similar 
structures. Recent studies have also implicated them in cellular signaling. MUC4 has 
been shown to act as an intramembrane receptor-ligand for the receptor tyrosine kinase 
ErbB2/HER2/Neu triggering specific phosphorylation of the ErbB2 in the absence of other 
ErbB ligands17. MUC1, through its highly conserved cytoplasmic tail, has been shown to 
bind to β-catenin17.  
 
Hyperosmolar stress and ocular surface epithelial cells 
Osmotic stress is one of the common stresses for organs, such as the kidney, skin, 
respiratory track, and eye. Osmotic stress can have longstanding detrimental effects that 
can cause tissue damage in these organs. Increased levels of tear osmolarity is a 
consistent feature of GVHD dry eye18. Nuclear factor of activated T-cells (NFAT) proteins 
is a family of transcription factors, which were originally identified to be expressed in most 
immune-system cells. This family contains five members: NFAT1 (NFATp), NFAT2 
(NFATc), NFAT3, 4, (NFATx), and NFAT5 (tonicity response element-binding protein or 
EBP27) was initially identified as a transcription factor involved in cellular responses to 
hypertonic stress28. NFAT5 is activated by phosphorylation under a hyperosmotic 
environment and is amongst the few known tonicity-regulated transcription factors in 
mammalian cells. NFAT5 transcriptionally regulates the expression of target genes 
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responsible for the metabolism of organic osmolytes, including aldose reductase, taurine 
transporter, betaine/GABA transporter, and sodium/myo-inositol transporter. NFAT5 also 
induces molecular chaperones, such as heat shock protein 70 and 9419-23. Does osmotic 
stress modulate NFAT5 expression in corneal and conjunctival epithelial cells is worth 
testing? 
Patients with dry eye have been shown to have elevated levels of proinflammatory 
cytokines. How tear hyperosmolarity affects the production of proinflammatory cytokines 
from ocular surface epithelial cells needs to be investigated. Proinflammatory cytokines 
released by immune cells in GVHD have been shown to exert a damaging effect on 
various tissues 17,19. The promoter region of genes encoding for mucins has response 
elements for signaling pathways activated by these proinflammatory cytokines, 
suggesting that these cytokines can modulate the gene expression of mucins 24,25. 
Additionally, these cytokines have been shown to induce the expression of enzymes, 
such as heparanase and hyaluronidase that may have a detrimental effect on the 
glycocalyx26.   
GVHD associated fibrosis 
GVHD patients suffer from longstanding fibrosis of skin, liver, lungs and 
gastrointestinal tract resulting in clinical manifestations of the disease such as 
scleroderma, bronchiolitis obliterans syndrome, and liver damage. Mouse models of 
chronic GVHD manifest fibrosis of skin, liver, lungs, and gastrointestinal tract27,28. There 
are anecdotal clinical reports of conjunctival fibrosis in GVHD patients29,30. However, 
there is no systemic preclinical study in a mouse model that examines the time course 
and severity of conjunctival fibrosis and its correlation to GVHD associated dry eye. 
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Myofibroblasts are key feature of fibrosis and can form by trans-differentiation of 
resident fibroblasts, mesenchymal cells, and circulating fibrocytes31-33. Myofibroblasts are 
contractile metabolically active cells that synthesis large quantities of extracellular matrix 
proteins and play a key role in fibrosis31-33. Conjunctiva has resident fibroblasts and donor-
origin fibrocytes have also been demonstrated in the eyes of GVHD patients34. Thus, 
conjunctival fibrosis may be likely caused myofibroblast formation and excessive 
deposition of extracellular matrix.  
Conjunctival tissue has been shown to express components of local renin 
angiotensin system (RAS), including renin, angiotensinogen, angiotensin converting 
enzyme (ACE) and AT1 receptors35-39. Conjunctival injury such as trabeculectomy has 
been shown to upregulate RAS40. Angiotensin II has been shown to cause 
transdifferentiation of conjunctival fibroblasts to myofibroblasts 41. Profibrotic cytokines 
such as transforming growth factor beta (TGF-β), PDGF, CTGF released by immune cells 
in GVHD can serve as the initial trigger for fibroblasts transdifferentiation to 
myofibroblasts42,43. An interaction between RAS and profibrotic cytokines, especially 
TGF-β and RAS, can serve to amplify and perpetuate conjunctival fibrosis. 
Hypothesis 
GVHD-associated dry eye is caused by ocular surface glycocalyx damage, mucin 
layer dysfunction, and conjunctival fibrosis. We tested this hypothesis using the following 
aims:  
Specific Aim1: To examine the role of glycocalyx and mucins in the etiology of GVHD-
associated dry eye. To test this aim 
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1a: we studied the effect of GVHD on ocular surface glycocalyx, ocular surface 
membrane-bound mucins, secreted tear film mucins, and conjunctival goblet cells;  
1b: we investigated the effect of augmentation of ocular surface mucins as a 
pharmacological approach to treat GVHD-associated dry eye. 
Specific Aim 2: To examine the effect of hyperosmolar stress on the release of pro-
inflammatory cytokines. To test this aim 
2a: we studied the effect of hyperosmolar stress on the release of proinflammatory 
cytokines from ocular surface epithelial cells.  
2b: we investigated the effect of proinflammatory cytokines on ocular surface glycocalyx 
and mucins 
Specific Aim 3: To examine the role of conjunctival fibrosis in etiology of GVHD-
associated dry eye. To test this aim, 
3a: we studied whether GVHD causes conjunctival fibrosis and myofibroblast formation. 
3b: we investigated the role of local ocular renin angiotensin system (RAS) in GVHD-
mediated conjunctival fibrosis. 
 
  









Figure 3. Ocular surface barrier consisting of glycocalyx and intracellular junctions42. 
  
Figure 2. Structure of the four types of ocular surface epithelial cells 
mucins (MUC)  
A) secreted, gel forming MUC5AC which produce by gablet cells.  
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Purpose: The present study was designed to investigate the role of ocular surface 
mucins in GVHD-associated dry eye. The ameliorative effect of topical rebamipide, a 
mucin secretagogue, on GVHD-associated dry eye was also tested. 
Methods: A mouse model of allogeneic transplantation was used to induce ocular 
GVHD with C57BL/6 as donors and B6D2F1 as recipient mice. Phenol red thread 
method and fluorescein staining were used to quantify tear secretion and corneal 
keratopathy. At 8 weeks after the allogeneic transplantation, corneas were harvested to 
perform glycocalyx staining and confocal microscopy. The goblet cell staining was 
performed using periodic acid Schiff’s staining. Corneal and tear film levels of Mucin1, 
4, 16, 19 and 5AC were quantified using ELISA and real-time PCR. Rebamipide was 
applied topically twice daily to mice eyes and BSS was used as vehicle control. 
Results: Allogeneic transplantation resulted in ocular GVHD-associated dry eye 
characterized by a significant decrease in tear film volume and the onset of corneal 
keratopathy. Ocular GVHD caused a significant decrease in the area and thickness of 
corneal glycocalyx. A significant decrease in the goblet cells was also noted. A 
significant decrease in mucin 4 and mucin 5AC levels was also observed. Topical 
treatment with rebamipide partially attenuated ocular GVHD-mediated decrease in tear 
film volume and significantly reduced the severity of corneal keratopathy. 
Conclusions: Ocular GVHD has a detrimental impact on ocular surface glycocalyx and 
mucins. Rebamipide, a mucin secretagogue, partially prevents ocular GVHD-associated 




Allogeneic hematopoietic stem cell transplantation is a successful treatment option for 
hematological malignancies. However, graft versus host disease (GVHD) is a serious 
complication of hematopoietic stem cell transplantation, and its incidence remains high 
in spite of the advances in HLA matching. Depending upon the time of onset and clinical 
manifestations, GVHD is divided into the acute and chronic phase. Acute GVHD 
primarily affects the liver, skin, and intestine1-3. On the other hand, chronic GVHD has 
been shown to cause a high incidence of ocular complications4,5. As high as 60-90% of 
chronic GVHD patients suffer from ocular manifestations4,5. Ocular signs in chronic 
GVHD patients may be noticeable even before the other systemic symptoms6-8. Dry eye 
disease is one of the most frequent complications of ocular GVHD9,10. The dry eye 
disease in ocular GVHD patients is severe, resulting in signs of blurred vision, 
photophobia, redness, gritty sensation, and pain9,10. These symptoms cause significant 
visual discomfort and reduce the overall quality of life of GVHD patients9,10. In the 
absence of timely and appropriate treatment, dry eye disease in GVHD patients may 
progress to corneal keratopathy, ulceration, and visual impairment. 
Lacrimal functional unit including ocular surface nerves, apical surface 
glycocalyx, lacrimal glands, meibomian glands and a normal blinking response all 
collectively contribute to the secretion and maintenance of a healthy tear film. Tear film 
is critical for keeping the ocular surface hydrated and lubricated, thus preventing 
desiccation-induced damage to the ocular surface. Tear film is comprised of mucous, 
aqueous and lipid layers. Mucous layer of tear film is primarily comprised of membrane-
bound and secreted mucins11-15. Mucins are high molecular weight glycoproteins made 
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up of a protein core with extensive glycan N-acetyl galactosamine side chains. The 
heavy glycosylation imparts the mucins with hydrophilicity and a high negative charge11-
15. 
These structural features account for their two key physiological functions of 
repelling pathogens and keeping the ocular surface hydrated11-15. The mucous layer of 
tear film contains membrane-bound mucins (MUC): MUC1, MUC4, MUC16, soluble 
MUC7 and, gel-forming secreted mucins, MUC19, MUC5AC and MUC5B11-15. The 
membrane-bound mucins are expressed on the apical surface of corneal and 
conjunctival epithelial cells. The gel-forming mucins MUC5AC and MUC5B are primarily 
secreted by the goblet cells present in the conjunctiva and lacrimal gland respectively. 
Lacrimal gland also releases soluble MUC7 in the tear film. Tear film mucins retard tear 
film evaporation keep the eye surface lubricated and entrap allergens and pathogens11-
15. 
Patients with dry eye disease show reduced levels of mucins or an alteration in 
the degree of their glycosylation16-18. A significant aqueous deficit has been observed in 
the tears of GVHD patients suffering from dry eye19. Multiple studies have shown that 
GVHD causes lacrimal gland fibrosis 20-23. How GVHD impacts ocular surface mucins is 
not known. Therefore, the aim of the present study was to investigate the role of ocular 
surface mucins in GVHD-associated dry eye and to test the ameliorative effect of 






Allogenic bone marrow transplantation 
The animal protocol was approved by Institutional Animal Care and Use 
Committee of Chapman University. All the animal experiments were conducted in 
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research. A previously published mouse model of MHC class I mismatch induced 
ocular GVHD was used23. The B6D2F1 mice (The Jackson Laboratories, Bar Harbor, 
ME, USA) having a heterozygous MHC haplotype b/d were used as recipients and 
C57BL/6 mice (The Jackson Laboratories, Bar Harbor, ME, USA) having a homozygous 
haplotype b/b were used as donors. The bone marrow and spleen cells were harvested 
from 8 weeks old donor female C57B6 mice. Ten weeks old female B6D2F1 recipient 
mice were exposed to a total body irradiation of 1100 cGy delivered in two equally 
divided doses three hours apart (RS 2000 X-ray Biological Irradiator, Rad Source 
Technologies, Buford, GA, USA). The irradiated B6D2F1 mice were then injected with 
2X106 spleen cells and 5X106 bone marrow cells obtained from C57B6 mice by retro-
orbital injection. The mice were housed in a sterile cage, fed with diet gel (ClearH2O, 
Portland, ME, USA) and received sulfatrim (0.672 mg/ml) in their drinking water for the 
first 14 days. At 8 weeks after the transplantation, animals were euthanized by CO2 
administration for the collection of ocular tissue. 
The study design included three different group of mice. 1) Control group (No 
transplant) n= 6 mice included age matched B6D2F1 mice, which did not receive any 
bone marrow or spleen cell transplantation. 2) Ocular GVHD group n= 12 included 
B6D2F1 mice that received allogenic bone marrow and spleen cell transplantation. 
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3) Rebamipide treated group n=6 included B6D2F1 mice that received allogenic bone 
marrow and spleen cell transplantation and were treated with 2 μl topical ophthalmic 
drops of 2% rebamipide suspended in BSS in left eye two times daily. The right eye of 
these mice received 2 μl topical ophthalmic drops of vehicle BSS two times daily. 
Tear quantification: 
Tear secretion was quantified by phenol red thread test before the allogeneic 
transplantation and at weekly intervals after the transplantation. The phenol red 
impregnated thread (FCI Ophthalmics, Pembroke, MA, USA) was placed in the lower 
eyelid of mice on the temporal side for 1 minute. Upon wetting by tears, the phenol red 
thread changes color from yellow to red due to pH change. After 1 minute, the thread 
was removed, and the length of the red color on the thread was measured. The length 
was converted to the volume by using a standard curve plotted by measuring the length 
of the phenol red thread wetted with a known volume of artificial tears. 
Fluorescein staining: 
Mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and 
xylazine (10 mg/kg). A 2 μl sterile solution of 0.5% fluorescein was applied to mouse 
eye, and imaging was performed under a green fluorescent filter using 
stereomicroscope equipped with a digital camera. The captured corneal images were 
divided into hypothetical four quadrants for scoring the keratopathy using a previously 
published method24. Each quadrant was scored as follows: No staining= 0; slightly 
punctate 
staining less than 30 spots= 1; punctate staining more than 30 spots, but not diffuse= 2; 
diffuse staining but no positive plaque= 3; positive fluorescein plaque= 4. The scores of 
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each quadrant was added to arrive at a final grade (total maximum possible score=16). 
Glycocalyx staining: 
The eyes were collected from euthanized animals at 8 weeks after the allogeneic 
transplantation and were fixed by immersing overnight in 4% paraformaldehyde. The 
corneas were isolated and blocked in 5% BSA for 20 minutes. Glycocalyx staining on 
the corneas was performed using 1.5 μg/ml solution of Alexa 488 conjugated wheat 
germ agglutinin lectin (Thermo Fisher Scientific, Hanover Park, IL, USA) for 20 minutes. 
Wheat germ agglutinin lectin binds to the N-acetylglucosamine and N-acetylneuraminic 
acid residues present on the ocular surface glycocalyx and have been used in multiple 
studies, including human patients, to stain corneal glycocalyx25-27. The stained corneas 
were imaged using a confocal microscope. A total of 4 images were captured from each 
cornea. The quantification of glycocalyx stained area and thickness was performed 
using Image J software in a blinded manner. 
Goblet Cell Staining: 
The eyes along with eyelids were harvested from euthanized animals at 8 weeks 
after the allogeneic transplantation and processed for paraffin embedding. The 7 μm 
thin paraffin sections were cut, and periodic Acid Schiff's (PAS) staining was performed 
for goblet cells using a commercially available kit (Polysciences, Inc., Warrington, PA, 
USA). The stained sections were imaged at 100X magnification using a brightfield 
microscope (Keyence corporation of America, Itasca, IL, USA). 
ELISA quantification of mucin 1, 4 & 16: 
At 8 weeks after the allogeneic transplantation, animals were euthanized by CO2 
administration. The eyeballs were collected, and the corneas were separated. The 
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corneas were homogenized in RIPA buffer containing protease inhibitor (Pierce, 
Thermo Fisher Scientific, Hanover Park, IL, USA). The total protein in the corneal 
homogenates was quantified by BCA method using a commercially available kit (Pierce, 
Thermo Fisher Scientific, Hanover Park, IL, USA). The Muc1, Muc4 and Muc16 levels 
were quantified in the corneal protein lysates using commercially available ELISA kits 
(LSBio, Seattle, WA, USA). The mucin levels were normalized for the milligram of total 
protein in the corneal lysates. 
ELISA quantification of mucin 5AC: 
The Muc5ac levels were quantified in the tears collected from mice at 8 weeks 
after the allogeneic transplantation. For tear collection, mice were lightly anesthetized 
with isoflurane. A 1 μL solution of 1X PBS containing 0.1% BSA was placed on each 
eye of the mouse and then collected back by using a Drummond microcapillary tube. 
The 1 μL collected from each eye was pooled and added to 8 μL of BSS solution. The 
tears were stored at -80°C for quantification of Muc5ac using a commercially available 
ELISA kit (LSBio, Seattle, WA, USA). 
Gene expression quantification of Mucin 1, 4, 16 & 19: 
Corneas were harvested from animals at 8 weeks after transplantation as described 
above. The mRNA was extracted from the corneas using the RNeasy Mini kit (RNeasy 
kit; Qiagen Inc., Valencia, CA, USA). The mRNA was immediately reverse transcribed 
to cDNA using a commercially available kit (Superscript III First-strand synthesis, 
Thermo Fisher Scientific, Hanover Park, IL, USA) for cDNA synthesis. The cDNA was 
used to quantify Muc1, Muc4, Muc16, and Muc19 gene expressions using real-time 
PCR. A 20 μl reaction mixture containing 2 μl of cDNA, 2 μl of forward primer (200 nM), 
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2 μl of reverse primer (200 nM), and 10 μl of 2X SYBR green supermix was run at a 
universal cycle (95°C for 10 min, 40 cycles at 95°C for 15 s, and 55°C for 60 s) in a 
thermocycler (Biorad CFX thermocycler, Bio-Rad Laboratories). β-actin was used as the 
housekeeping gene. The relative change in gene expression was calculated using ΔΔCt 
method. 
Statistical Analysis: 
The data is presented as mean + S.E.M. One-way ANOVA followed by Dunnet’s 
and Duncan’s test was used to analyze time dependent changes in tear film volume for 
Figure 1 and corneal keratopathy score for Figure 7B, respectively. The data presented 
in Figures 2-6 for comparing control and allogeneic transplantation groups was 
analyzed using unpaired t test. Two-way ANOVA was used for data analysis of tear film 
volume presented in Figure 7 A. 
Results: 
Effect of ocular GVHD on tear film volume and corneal keratopathy: 
The present study used MHC mismatched allogeneic transplantation mouse model that 
has been shown to develop ocular GVHD23. Our results further confirm that this mouse 
model of allogeneic transplant results in significant manifestations of dry eye due to 
ocular GVHD as is evident from a decrease in tear film volume and appearance of 
corneal keratopathy. Fig. 1 shows a baseline mean tear film volume of 300 nanoliters in 
the mice prior to the allogeneic transplantation. After the bone marrow and spleen cell 
transplantation, a statistically significant 3-fold decrease in tear film volume was noted 
starting at 3 weeks, and this decrease persisted till the tested time point of 8 weeks. The 
observed 2 weeks delay in the onset of tear film decrease is anticipated because 
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immune-mediated damage to the lacrimal functional unit is expected to precede prior to 
a decrease in tear film volume becomes apparent. 
Fig. 2 shows a representative fluorescein-stained image of a mouse cornea 
before (Fig. 2A) and at 8 weeks after the allogeneic bone marrow and spleen cell 
transplantation (Fig. 2B). As can be seen in fig. 2B, the corneas of mice that underwent 
allogeneic transplant showed significant punctate and plaque staining. The scoring of 
fluorescein-stained corneal images was performed in a blinded manner using a 
previously described method24. The corneas of mice that received allogeneic 
transplantation had a mean fluorescein staining score of 8 (Fig. 2C), suggesting that 
ocular GVHD caused a moderate to severe degree of corneal keratopathy. 
Effect of ocular GVHD on corneal glycocalyx and goblet cells: 
Corneal epithelial cells express 3 different types of membrane-tethered mucins 
on their apical surface. These mucins together with galectin 3 form a continuous 
network of glycocalyx. Wheat germ agglutinin lectin binds to the sialic acid residues 
present on these mucins and has been previously used to stain the corneal 
glycocalyx27. Fig. 3 shows the top and orthogonal projection confocal images of the 
mouse corneas stained for glycocalyx using Alexa 488 conjugated wheat germ 
agglutinin. The top view of confocal z stack images show a dense and uniformly 
distributed glycocalyx staining in the corneas of control mice that did not receive any 
transplantation (Fig. 3A). On the other hand, corneal glycocalyx was sparse and patchy 
in the corneas obtained from mice at 8 weeks after they received allogeneic bone 
marrow and spleen cell transplantation (Figure 3B). The glycocalyx-stained area was 
quantified as percentage of the total corneal area using binary image analysis of 16 
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images each of corneas obtained control mice and the mice that received allogeneic 
transplantation (4 images captured from different parts of each cornea and n=4 mice). 
As is evident from binary quantification data presented in Fig. 3C, a significant decrease 
of 37% in glycocalyx stained area was observed in the mice corneas that received 
allogeneic transplantation compared to the control mice without any transplantation. Fig. 
3D and 3E show the orthogonal projection confocal Z stack images of glycocalyx-
stained corneas. A significant decrease in the glycocalyx thickness was observed in the 
corneas obtained from mice that received allogeneic transplantation (Fig. 3D) compared 
to control corneas obtained from mice without any transplantation (Fig. 3E). Glycocalyx 
thickness was also quantified in16 images each obtained from corneas of control mice 
(n=4) and from the corneas of mice that received allogeneic transplantation (n=4). Fig. 3 
F shows a mean decrease of 33% in the corneal glycocalyx thickness in the mice that 
received allogeneic transplantation compared to control mice. 
Fig. 4 shows a representative image of periodic acid Schiff’s-stained goblet cells 
in the eyelids of control mice and mice that underwent allogenic bone marrow and 
spleen cell transplant. It is apparent from the staining that allogenic bone marrow and 
spleen cell transplantation mediated ocular GVHD caused a notable decrease in the 
number of goblet cells. It can also be noted that the morphology and mucin content of 
goblet cells has also been altered by the ocular GVHD in mice that received allogenic 
bone marrow and spleen cell transplant as compared to the control mice that did not 




Effect of ocular GVHD on mucins: 
We further investigated the effect of allogeneic bone marrow and spleen cell 
transplantation associated with ocular GVHD on membrane bound Muc1, 4 and 16 
mucins using corneal homogenates and on secreted Muc5ac in tear film. A slight 
reduction inMuc1 (Fig. 5A) levels was noted in the corneal homogenates obtained from 
mice at 8weeks after allogeneic bone marrow and spleen cell transplantation as 
compared to the levels in the control corneal homogenates obtained from mice that did 
not receive any transplantation. A statistically significant decrease in corneal 
homogenate levels of Muc4 (Fig. 5B) and tear film levels of Muc5ac (Fig. 5D) was also 
observed in the mice that underwent allogeneic transplant as compared to the control 
mice. On the other hand, a slight increase in Muc16 was observed (Fig. 5C) in the 
corneal homogenates of transplanted mice compared to control mice. 
To test the effect of ocular GVHD on mucin gene expression, mRNA levels were 
quantified in the corneas of control mice and in the cornea obtained from mice at 8 
weeks after the allogeneic transplant. A significant increase in Muc1 gene expression 
was observed in the corneas obtained from mice that received allogeneic 
transplantation compared to control mice that did not receive any transplantation (Fig. 6 
A). However, no significant change was noted in the mRNA levels of Muc4 (Fig. 6B), 
Muc16 (Fig. 6C) and Muc19 (Fig. 6D) between the control mice without the 





Effect of topical rebamipide on ocular GVHD-mediated changes in tear film and 
corneal keratopathy: 
 
Lastly, we tested the effect of rebamipide, a mucin secretagogue, on ocular GVHD 
mediated decrease in tear film volume and cornel keratopathy. As can be seen from the 
Fig. 7 A, twice daily topical ophthalmic application of rebamipide attenuated ocular 
GVHD-mediated decrease in tear film volume. The results were statistically significant 
at week 3 and 4 compared to the GVHD mice who received allogeneic transplantation 
but did not receive any eye drops. The BSS was used as a vehicle for compounding 
rebamipide. Therefore, we also tested the effect of topical ophthalmic application of 
BSS as vehicle, but BSS application in GVHD mice had no notable effect on the tear 
film volume compared to untreated (no eye drops) control GVHD mice. Further, 
rebamipideapplication also significantly mitigated ocular GVHD-mediated corneal 
keratopathy (Fig. 7B). Rebamipide treated GVHD mice showed a mean corneal 
keratopathy score of 3compared to a score of 8 for the untreated (no eye drops) GVHD 
mice (Fig. 7B). It is interesting to note though that keeping the ocular surface hydrated 
by BSS vehicle application also partly attenuated corneal keratopathy. BSS treated 
GVHD mice showed 
a mean corneal keratopathy score of 5 compared to a score of 8 for the untreated (no 
eye drops) GVHD mice (Fig. 7B). 
Discussion: 
The apical surface of the corneal and conjunctival epithelium is covered with glycocalyx, 
a thin layer of glycoproteins largely composed of membrane-tethered mucins and 
galectin-328-30. The glycocalyx forms a boundary between the ocular surface epithelium 
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and the tear film. Glycocalyx serves to protect the cells against mechanical and 
chemical damage. An intact glycocalyx is also essential to reduce the friction during 
blinking and to keep the ocular surface hydrated28-30. We used fluorescent wheat germ 
agglutinin labeling and whole cornea mount 3D confocal microscopy to visualize 
glycocalyx on the corneas of GVHD mice. Wheat germ agglutinin binds to N-acetyl-
glucosamines and sialic acid side chains of the membrane-tethered mucins and has 
been used to specifically label, visualize and quantify glycocalyx in the cornea and 
vascular endothelium25-27. Our data demonstrate a significant decrease in the area and 
thickness of ocular surface glycocalyx in mice that received allogeneic bone marrow 
and spleen cell transplantation suggesting that GVHD has a detrimental effect on the 
ocular surface glycocalyx. 
Membrane-tethered mucins are an integral component of glycocalyx. Thus, we 
further examined the effect of GVHD on corneal epithelial membrane-tethered mucins. 
Our results demonstrate that GVHD caused a significant decrease in protein levels of 
membrane-tethered Muc4 but did not cause any notable change in protein levels of 
membrane-tethered Muc1 or Muc16. Interestingly, a significant increase in Muc1 gene 
expression was observed in the corneas of GVHD mice, which can possibly be a 
compensatory response to partially circumvent the GVHD-mediated damage to the 
ocular surface glycocalyx. Besides membrane-tethered mucins, tear film also contains 
soluble mucins. Goblet cells are the primary source of large gel forming mucin Muc5AC 
which is secreted into the tear film31,32. The results of the present study demonstrate 
that GVHD has a detrimental effect on goblet cells because a decrease in the number of 
goblet cells was observed in the tissue sections obtained from mice suffering from 
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GVHD due to allogeneic transplantation. The histology data also consistently 
demonstrated partially empty goblet cells, suggesting the possibility that the surviving 
goblet cells in the GVHD mice were releasing Muc5AC in the tear film possibly in an 
effort to salvage the ongoing damage to the ocular surface. Our observations are further 
supported by the ELISA quantification data showing a significant decrease in the tear 
film levels of Muc5AC in GVHD mice. Alterations in ocular surface mucins and 
glycocalyx has been previously reported in non-autoimmune dry eye and dry eye due to 
Sjogren’s disease16-18,29. To the best of our knowledge, this is the first study to 
demonstrate that GVHD causes a damage to the ocular surface glycocalyx and alters 
ocular surface mucins. 
In this study, we used an allogeneic MHC heterozygous mismatch hematopoietic 
transplant mouse model to induce ocular GVHD. Our data demonstrate that this 
mouse model develops ocular GVHD-associated dry eye as demonstrated by a 
significant decrease in tear film and the corneal keratopathy. Previous studies have 
shown the development of ocular GVHD in this mouse model and support the results of 
the present study23. Using this mouse model, Hassan et al23 have demonstrated that 
GVHD hasa  detrimental effect on the lacrimal gland. Studies using MHC matched 
allogeneic hematopoietic transplant mouse has also shown lacrimal gland damage in 
ocular GVHD33-35. However, our data is the first one to demonstrate that besides 
lacrimal gland, GVHD also causes damage to the ocular surface glycocalyx. 
Rebamipide, an amino acid analog of 2 (1H)-quinolinone, has long been used for 
the treatment of gastric ulcers36,37. The ophthalmic formulation of rebamipide has 
recently been launched for the treatment of dry eye in Japan 38. Rebamipide has been 
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shown to stimulate gastric mucosal prostaglandin production, increase gastric mucus 
synthesis, and scavenge reactive oxygen radicals40-42. Recent studies have shown that 
rebamipide increases MUC1, MUC4 and MUC16 synthesis in stratified cultures of 
human corneal epithelial cells43,44. In vivo administration of rebamipide has been 
demonstrated to have an ameliorative effect in mouse model of Sjogren’s syndrome, 
superoxide dismutase knockout mice and rabbit model of dry eye46-47. Given the 
beneficial effects of rebamipide on mucous layer and dry eye, we tested the effect of 
topical administration of rebamipide in GVHD-associated dry eye in mouse model. Our 
data demonstrate that topical rebamipide administration provided significant protection 
against GVHD associated dry eye as indicated by the sustenance of tear film and a 
notable decrease in corneal keratopathy score. Interestingly, topical administration of 
BSS vehicle alone also had some ameliorative effect suggesting that keeping the ocular 
surface hydrated can partially rescue GVHD-associated corneal keratopathy. 
In summary, our results demonstrate that allogeneic transplantation-associated 
ocular GVHD can have a significant detrimental effect on ocular surface glycocalyx and 
ocular surface mucins. Further, modulation of ocular surface mucins by rebamipide, a 
mucin secretagogue, can partially prevent ocular GVHD-associated decrease in tear 
film and reduced the severity of corneal keratopathy. 
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Figure 1. Tear film volume in mice before (baseline) and at various time points after 
allogeneic bone marrow & spleen cell transplantation.  
A significant (* p<0.05 compared to baseline) decrease in tear film volume was 
observed at 3 weeks after allogeneic transplantation and it remained significantly low for 
the tested duration of 8 weeks. 
 
 
Figure 2. Representative fluorescein-stained images of mouse corneas before (A) and 
at 8 weeks (B) after allogeneic bone marrow & spleen cell transplantation. 
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Quantification of fluorescein staining (C) showed significant (* p<0.05 compared to 
before transplantation) corneal keratopathy at 8 weeks after allogeneic transplantation 
 
 
Figure 3. Representative confocal Z stacks images of top (A & B) and orthogonal (D & 
E) view of mouse corneas stained for glycocalyx (green) using wheat germ agglutinin. 
Nuclei are stained blue. Panel A and B is top view of corneas obtained from control 
mice that did not receive any transplantation and mice at 8 weeks after allogeneic bone 
marrow & spleen cell transplantation. Quantification of percent-stained area (Panel C) 
shows a significant decrease (*p<0.05 compared to control mice that received no 
transplantation) in the glycocalyx in mice corneas at 8 weeks after allogeneic 
transplantation. Panel D & E is orthogonal view of corneas obtained from control mice 
that did not receive any transplantation and mice at 8 weeks after allogeneic 
transplantation. Quantification (Panel F) shows a significant decrease (*p<0.05 
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compared to control mice that received no transplantation) in the glycocalyx thickness in 
mice corneas at 8 weeks after allogeneic transplantation. Area and thickness 
quantifications were calculated using 16 different images, each of control mice (n=4) 




Figure 4. Representative images showing periodic acid Schiff’s-stained goblet cells in 
the tissue sections obtained from control mice (no transplant) and mice at 8 weeks after 




Figure 5. ELISA quantification of mucin 1, mucin 4, mucin 16, and mucin 5AC in the 
corneal homogenates and tears obtained from control mice (no transplant) and mice at 
8 weeks after allogeneic bone marrow and spleen cell transplantation. A decrease in 
mucin 4 (* p <0.05) and mucin 5AC (* p <0.05) was observed compared to the levels in 
control mice that received no allogeneic transplantation.   
 34 
 
Figure 6. Gene expression quantification of mucin 1, mucin 4, mucin 16, and mucin 19 
in the corneal homogenates obtained from control mice (no transplant) and mice at 8 
weeks after allogeneic bone marrow and spleen cell transplantation. A significant 
increase in mucin1 gene expression (* p <0.05) was observed compared to the levels in 




Figure 7. Effect of rebamipide ophthalmic drops on allogeneic bone marrow and spleen 
cell transplantation-mediated decrease in tear film volume (A) and corneal keratopathy 
score (B). Rebamipide attenuated allogeneic transplantation mediated decrease in tear 
film volume, and the results were statistically significant (* p<0.05) at 3 and 4 weeks 
after the allogeneic transplantation as compared to mice that also received the 
allogeneic transplantation but were either treated with BSS vehicle or did not receive 
any eye drops. Rebamipide treatment also significantly decreased the corneal 
keratopathy score (* p<0.05 compared to no eye drops-treated mice; t p<0.05 
compared to BSS vehicle). Animals that received BSS vehicle alone also showed 
significantly (* p<0.05) lower corneal keratopathy score compared to mice that received 
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EFFECT OF OSMOTIC STRESS ON NFAT5 AND PROINFLAMMATORY 
CYTOKINES GENE EXPRESSION IN OCULAR SURFACE EPITHELIAL CELLS 
Abstract 
An increase in tear osmolarity is a cardinal feature of dry eye disease. Osmotic stress 
has been shown to cause an increase in the expression of proinflammatory cytokines. 
The ocular surface is covered by conjunctival and corneal epithelial cells, which may 
show a different biological response to osmotic stress. Therefore, we investigated the 
effect of hyperosmolar stress on gene expression of NFAT5, a tonicity-regulated 
transcription factor and cytokines IL1, IL6, TNFα, and IFN-γ in human conjunctival and 
corneal epithelial cells. 
 Methods: Telomerase immortalized human corneal and conjunctival epithelial cells 
were exposed to hyperosmolar cell culture media (430 mOsm) for 12 and 24 hours. The 
mRNA was isolated from these cells and was reverse transcribed to cDNA. The cDNA 
was used for the quantification of gene expression by real-time PCR. 
Results: Hyperosmotic stress caused a 15.8- and 2.2-fold increase in NFAT5 gene 
expression in corneal and conjunctival epithelial cells. Hyperosmotic stress also caused 
1.5- and 2-fold increase in the gene expression of IL1 in the human conjunctival and 
corneal epithelial cells, respectively. Hyperosmotic stress also caused a 3- 4 fold 
increase in IL6 expression in conjunctival cells, whereas the increase in IL6 gene 
expression was much more robust in human corneal epithelial cells. Similarly, 
hyperosmotic stress caused a 2-3 fold increase in TNFα in human conjunctival cells, 
whereas a >10-fold increase in TNFα expression was observed in the human corneal 
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epithelial cells. Lastly, a 3-4 fold increase in IFN-γ was observed in corneal epithelial 
cells compared to a 1.8 fold increase noted in conjunctival epithelial cells. 
Conclusion: Our data demonstrated that human conjunctival and corneal epithelial cells 
show a differential response to the hyperosmotic stress-mediated change in the gene 
expression of NFAT 5 and proinflammatory cytokines. Human corneal epithelial cells 
are more sensitive to hyperosmotic stress. 
Introduction 
Tear Film and Ocular Surface Society defines dry eye disease is a multifactorial 
disorder of the ocular surface characterized by impairment and loss of tear 
homeostasis, ocular discomfort or pain, and neurosensory abnormalities1-3. Healthy tear 
fluid is iso-osmolar, but dry eye disease can cause an increase in tear osmolarity4-5. An 
increase in tear osmolarity has also been observed in the tears of GVHD patients. 
NFAT5 is activated by phosphorylation under a hyperosmotic environment and is 
amongst the few known tonicity-regulated transcription factors in mammalian cells6. 
NFAT5 transcriptionally regulates the expression of target genes responsible for organic 
osmolytes' metabolism, including aldose reductase, taurine transporter, betaine/GABA 
transporter, and sodium/myo-inositol transporter. Osmotic stress also activates stress-
related kinases, and these kinases are responsible for transcription of the 
proinflammatory cytokines, thus forming a link between osmolarity and gene expression 
of these cytokines6,7. Therefore, we tested the effect of hyperosmolar stress on the 
changes in gene expression of NFAT5, IL-1, IL-6, TNF- α, and IFN-γ in human corneal 




Culture of stratified human corneal and conjunctival epithelial cells 
 
Telomerase-transformed human corneal and conjunctival epithelial cell lines were used 
for this study. Human corneal epithelial cells were propagated in keratinocyte growth 
medium supplemented with bovine pituitary extract (0.004 ml/ml), human epidermal 
growth factor (0.125ng/ml), human insulin (5µg/ml), hydrocortisone (0.33µg/ml), 
epinephrine (0.39 µg/ml), transferrin (10 µg/ml) and calcium chloride (0.15 mM) 
(PromoCell GmbH, Heidelberg, Germany). To induce stratification, the cells were plated 
on a collagen-coated 3.0 µm PTFE transwell membrane inserts (Corning Inc., Corning, 
NY, USA), and the media was switched to a supplemented keratinocyte growth medium 
containing a higher concentration of CaCl2 (1.15 mM). This media was added both on 
the inserts and the bottom well until the cells reached 100% confluence. Once the cells 
reached 100% confluence, the media was added to the bottom of the well only, leaving 
the membrane inserts containing the cells exposed to air for one week to achieve 
stratification into a multilayered epithelium. 
The human conjunctival epithelial cells were propagated in keratinocyte serum-
free medium supplemented with 25 μg/mL bovine pituitary extract, 0.2 ng/mL epidermal 
growth factor, and 0.4 mM CaCl2 (Gibco-Invitrogen Corp., Rockville, MD, USA). Once 
the cells reached 50% confluence, the media was switched to a 1:1 mixture of 
supplemented keratinocyte serum-free medium and low-calcium DMEM without 
HEPES/F12 media (Gibco-Invitrogen Corp., Rockville, MD, USA). When the cells 
reached 100% confluence, the media was replaced with DMEM/F12 media 
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supplemented with 1mM CaCl2, 10% Calf serum, and 10 ng/mL EGF for about 5 to 7 
days to induce stratification. 
Osmotic stress treatment 
 
Human corneal and conjunctival epithelial cells were exposed to hyperosmolar 
cell culture media (430 mOsm) for 12 hours and 24 hours. The hyperosmolar media 
was prepared by adding sodium chloride to the isotonic cell culture media. The control 
cells were cultured in the isotonic media (300 mOsm). Each experiment was conducted 
in triplicate.  
Isolation of mRNA and preparation of cDNA  
 
The total RNA from the control and hyperosmolar exposed corneal and 
conjunctival epithelial cells were isolated using a commercially available kit (Qiagen’s 
RNeasy Mini Kit, Valencia, CA, USA) as per manufacturer’s instructions. The RNA was 
immediately reverse transcribed to cDNA using a commercially available kit 
(SuperScript® III First-Stand, Invitrogen, Carlsbad, CA, USA).  
Cytokine gene expression quantification 
 
The gene expression of cytokines was quantified using Real-Time PCR. A 20 µl 
reaction mixture containing 2 µl of cDNA and 18 µl of SYBR Green Master Mix was run 
at a universal cycle (95°C for 10 min, 40 cycles at 95°C for 15 seconds, and 55°C for 60 
seconds) using Real-Time thermocycler (Biorad CFX thermal cycler, Bio-Rad 
Laboratories, Hercules, California, USA). β-actin was used as the housekeeping gene. 
The relative change in gene expression was calculated using the ΔΔCt method. 
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Results and Discussion 
Exposure of human corneal and conjunctival epithelial cells to hyperosmotic 
stress caused an average of 15.8- and 2.2-fold increase in NFAT5 gene expression 
(Figure 1). For IL-1, there was a 2-fold increase in the gene expression corneal 
epithelial cells noted at 24-hour after exposure to hyper-osmolar media. On the other 
hand, a 1.5-fold increase in gene expression of IL-1 was noted at 12-hour after 
hyperosmolar media exposure in conjunctival epithelial cells (Figure 2). Next, for IL-6, 
there was >150-fold, and 3.5-fold increase in gene expression noted at 24-hour after 
hyperosmolar media exposure in corneal and conjunctival epithelial cells, respectively 
(Figure 3). For TNF-α, there was an 8-fold increase in the 12-hour treated corneal 
epithelial cells, a greater than 10-fold increase in the 24-hour treated corneal epithelial 
cells, and a 2-fold increase in gene expression in 24-hour treated conjunctival epithelial 
cells (Figure 4). Lastly, a 3-4 fold increase in IFN-γ was observed in corneal epithelial 
cells compared to a 1.8 fold increase noted in conjunctival epithelial cells. 
Based on this data, it can be deduced that hyperosmolar stress increases the gene 
expression of NFAT5 and proinflammatory cytokines in human corneal and conjunctival 
epithelial cells, and it can be concluded that human corneal epithelial cells are more 




Figure 1. Effect of hyperosmolar stress on gene expression of NFAT5 in human corneal 




Figure 2. Effect of hyperosmolar stress on gene expression of IL-1 in human corneal 
and conjunctival epithelial cells* p< 0.05 versus cells exposed to iso-osmolar media 
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Figure 3. Effect of hyperosmolar stress on gene expression IL-6 in human corneal and 
conjunctival epithelial cells. * p< 0.05 versus cells exposed to iso-osmolar media 
 
 
Figure 4. Effect of hyperosmolar stress on gene expression of TNF-α in human corneal 




Figure 5. Effect of hyperosmolar stress on gene expression of IFN-γ in human corneal 
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Purpose: Proinflammatory cytokines are elevated in tears of patients with dry eye. 
Apical surface of ocular surface epithelial cells is covered with membrane-tethered 
mucins (MUC) that, together with galactin-3, form glycocalyx network, which plays a 
critical role in ocular health. The present study tested the effect of proinflammatory 
cytokines IL-6, TNF-α, and IFN-γ on membrane-tethered mucins gene expression, 
glycocalyx, and viability of ocular surface epithelial cells. 
Methods: Stratified cultures of human corneal and conjunctival epithelial cells were 
exposed to five different concentrations of IL-6, TNF-α, and IFN-γ for 24 hours. The 
mRNA was isolated, and reverse-transcribed to cDNA for gene expression 
quantification using real time PCR. The glycocalyx was stained using Alexa 488- 
conjugated wheat germ agglutinin lectin and images using confocal microscopy. 
Apoptotic and necrotic cell death was quantified using flow cytometry.  
Results: IL-6, TNF-α, and IFN-γ treatment resulted in a significant increase in the MUC1 
and MUC4 gene expression in stratified human corneal epithelial cells but did not cause 
a significant change MUC16 expression. Unlike corneal epithelial cells, these cytokines 
caused no significant changes in MUC1, MUC4, and MUC16 expression in stratified 
human conjunctival epithelial cells. Further, IL-6, TNF-α, and IFN-γ did not cause a 
notable change in glycocalyx or apoptotic cell death in stratified human corneal and 
conjunctival epithelial cells, but IL-6 resulted in an increase in necrotic cell death in 
stratified human corneal epithelial cells while TNF-α caused a significant increase in 
necrotic cell death of stratified human conjunctival epithelial cells. 
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Conclusions: Our results have shown that IL-6, TNF-α, and IFN-γ have differential 
effects on human corneal and conjunctival epithelial cell mucin gene expression, 
resulting in an increase in MUC1 and MUC4 gene expression only in stratified human 
corneal epithelial cells. Furthermore, these cytokines did not cause significant changes 
in stratified human corneal and conjunctival epithelial cell glycocalyx. 
Keywords: Mucins, Glycocalyx, Ocular Surface, Proinflammatory Cytokines 
Introduction 
The apical surface of human corneal and conjunctival epithelial cells is covered 
with a layer of glycocalyx that forms a boundary between these cells and the tear film 
[1-3]. Glycocalyx is a network made up of membrane-tethered mucins, their side chains, 
and galectin-3 [1-7]. Glycocalyx and mucins are critical for ocular health as they serve 
many functions, including repelling pathogens, keeping the ocular surface hydrated, 
protecting the cells against mechanical and chemical damage, as well as reducing 
friction during blinking [1-7].  
Dry eye or keratoconjunctivitis sicca is a common ocular condition with a high 
global prevalence. The disease is characterized by loss of tear film homeostasis, tear 
hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities [8,9].  
While multiple factors contribute to the pathogenesis of dry eye, the immune-mediated 
inflammatory response plays a central role in its onset and progression [10-14]. 
Hyperosmolar stress has been shown to trigger the release of proinflammatory 
cytokines IL-1, IL-6, TNF-α from ocular surface epithelial cells [15,16]. Hyperosmolar 
stress due to increased tear osmolarity in dry eye disease and the associated release of 
cytokines can contribute to the early stage of ocular surface inflammation. Levels of IL-6 
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and TNF-α have been reported to be elevated in the tears of patients suffering from dry 
eye [17].  These proinflammatory cytokines along with chemokines, are also responsible 
for activation, maturation, and migration of antigen-presenting cells in the early stages 
of dry eye disease [10-14]. Subsequently, activated antigen-presenting cells recruit T 
cells which have been shown to secret IL-17 and IFN-γ [10-14]. T cell-derived cytokines 
contribute to the amplification stage of inflammation in dry eye disease [10-14].  
The promoter region of genes encoding for mucins have response elements for 
signaling pathways activated by proinflammatory cytokines, including IL-6, TNF-α, and 
IFN-γ, suggesting that these cytokines can modulate the gene expression of mucins 
[18-21]. Additionally, these cytokines have been shown to induce the expression of 
enzymes such as heparanase and hyaluronidase that may have a detrimental effect on 
the glycocalyx [22,23]. Immunological and conjunctiva impression cytology studies have 
shown that the levels of mucins or the degree of their glycosylation is notably altered in 
both the cornea as well as conjunctiva of patients suffering from Non Sjogren and 
Sjogren syndrome-related dry eye disease [1,2,24]. Therefore, the present study is 
designed to investigate the effect of two early-stage (IL-6, TNF-α) and one amplification 
stage (IFN-γ) proinflammatory cytokines on membrane-tethered mucins (MUC) MUC1, 
MUC4, MUC16, ocular surface glycocalyx, and cell viability of human stratified corneal 
and human stratified conjunctival epithelial cells. Since patients suffering from dry eye 
have elevated tear levels of these cytokines in the picogram range, the present study 
tested the effect of these cytokines on ocular surface mucins and glycocalyx at the 




Culture of stratified human corneal and conjunctival epithelial cells 
 
Telomerase-transformed human corneal and conjunctival epithelial cell lines 
were used for this study. Human corneal epithelial cells were propagated in keratinocyte 
growth medium supplemented with bovine pituitary extract (0.004 ml/ml), human 
epidermal growth factor (0.125 ng/ml), human insulin (5 µg/ml), hydrocortisone 
(0.33µg/ml), epinephrine (0.39 µg/ml), transferrin (10 µg/ml) and calcium chloride (0.15 
mM) (PromoCell GmbH, Heidelberg, Germany).  To induce stratification, the cells were 
plated on a collagen-coated 3.0 µm PTFE transwell membrane inserts (Corning Inc., 
Corning, NY, USA) and the media was switched to supplemented keratinocyte growth 
medium containing a higher concentration of CaCl2 (1.15 mM). This media was added 
both on the inserts as well as the bottom well until the cells reached 100% confluence. 
Once the cells reached 100% confluence, the media was added to the bottom of the 
well only, leaving the membrane inserts containing the cells exposed to air for one week 
to achieve stratification into a multilayered epithelium [25]. 
The human conjunctival epithelial cells were propagated in keratinocyte serum-
free medium supplemented with 25 μg/mL bovine pituitary extract, 0.2 ng/mL epidermal 
growth factor, and 0.4 mM CaCl2 (Gibco-Invitrogen Corp., Rockville, MD, USA). Once 
the cells reached 50% confluence, the media was switched to a 1:1 mixture of 
supplemented keratinocyte serum-free medium and low-calcium DMEM without 
HEPES/F12 media (Gibco-Invitrogen Corp., Rockville, MD, USA). When the cells 
reached 100% confluence, the media was replaced with DMEM/F12 media 
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supplemented with 1mM CaCl2, 10% Calf serum, and 10 ng/mL EGF for about 5 to 7 
days to induce stratification [26,27].  
Cytokines treatment 
 
The cytokines were purchased from PeproTech (Cranbury, NJ, USA). To test the 
effects of proinflammatory cytokines on mucin expression, glycocalyx, and epithelial 
viability, the stratified cultures of human corneal and conjunctival epithelial cells were 
separately exposed to IL-6, TNF-α, and IFN-γ at five different concentrations (30, 60, 
125, 250, 500 pg/mL) for 24 hours.  Each experiment was conducted in quadruplicates.  
Isolation of mRNA and preparation of cDNA  
 
The total RNA from the control and cytokine exposed stratified corneal and 
conjunctival epithelial cells was isolated using a commercially available kit (Qiagen’s 
RNeasy Mini Kit, Valencia, CA, USA) as per the manufacturer’s instructions. The RNA 
was immediately reverse transcribed to cDNA using a commercially available kit 
(SuperScript® III First-Stand, Invitrogen, Carlsbad, CA, USA).  
Mucins gene expression quantification 
 
The gene expression of MUC1, MUC4, and MUC16 was quantified using Real-
Time PCR. A 20 µl reaction mixture containing 2 µl of cDNA and 18 µl of SYBR Green 
Master Mix was run at a universal cycle (95°C for 10 min, 40 cycles at 95°C for 15 
seconds and 55°C for 60 seconds) using Real-Time thermocycler (Biorad CFX thermal 
cycler, Bio-Rad Laboratories, Hercules, California, USA). β-actin was used as the 







The stratified cultures of control and cytokine-exposed human corneal and 
conjunctival epithelial cells were fixed in 4% paraformaldehyde. The cells were blocked 
in 5% BSA for 20 minutes. Glycocalyx was stained using 1.5 μg/mL solution of Alexa 
488- conjugated wheat germ agglutinin lectin (Thermo Fisher Scientific, Hanover Park, 
IL, USA) for 20 minutes. Wheat germ agglutinin lectin binds to the N-acetylglucosamine 
and N-acetylneuraminic acid residues present on the ocular surface glycocalyx and has 
been used in multiple studies, including human patients to stain corneal glycocalyx 
[28,29]. The stained glycocalyx was imaged using a confocal microscope (Nikon Inc. 
Mellville, NY). Four images were captured from the randomly selected areas of each 
cultured well (total n=16 for each cytokine since the experiment was in quadruplicates). 
The quantification of glycocalyx stained area was performed using Image J software in 
a blinded manner. 
Flow cytometry quantification of apoptotic and necrotic cell death 
 
The stratified cultures of control and cytokine exposed human corneal and 
conjunctival epithelial cells were incubated in a solution containing 1:2000 propidium 
iodide and 1: 300 FITC-conjugated annexin V (Cayman Chemical, Ann Harbor, MI, 
USA). The populations of stained cells were analyzed using BD FACSverse flow 







The data are presented as mean + Standard error of mean. Statistical analysis 
was performed using GraphPad Prism software (GraphPad Prism, Version 8, San 
Diego, CA, USA). The data were analyzed using One-Way ANOVA, followed by 
Dunnett’s post-hoc test. A p value of <0.05 was considered statistically significant.  
Results 
Effect of IL-6, TNF-α, and IFN-γ on membrane-tethered mucins gene expression in 
stratified human corneal and conjunctival epithelial cells 
 
To test the effect of IL-6, TNF-α, and IFN-γ on ocular surface mucins gene 
expression, the stratified human corneal and conjunctival epithelial cells were exposed 
to five concentrations of these cytokines. Fig. 1 shows the effect of IL-6 on membrane-
tethered mucins in stratified human corneal and conjunctival epithelial cells. IL-6 
treatment caused a significant increase in the gene expression of MUC1 and MUC4 in 
the human corneal epithelial cells but did not cause a notable change in the gene 
expression of MUC16 (Fig. 1A). IL-6 showed an inverted bell-shaped dose-response 
curve with a less pronounced effect at 30 pg/ml followed by a dose-dependent 
significant (p<0.05 compared to control cells not exposed to IL-6) increase at 60, 125 
and 250 pg/ml then a subsequent decrease in effect at 500 pg/ml for both MUC1 and 
MUC4 gene expression. In contrast to the corneal epithelial cells, IL-6 did not 
significantly change the MUC1, MUC4, and MUC16 gene expression in stratified human 
conjunctival epithelial cells (Fig. 1B). 
Fig. 2A shows that TNF-α treatment caused significant (p<0.05 compared to 
control cells not exposed to TNF-α) increase in the gene expression of MUC1 and 
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MUC4 in stratified human corneal epithelial cells but did not cause any notable change 
in MUC16. It is worth noting that the various tested concentrations of TNF-α caused a 
similar increase in the gene expression of MUC1 and MUC4 suggesting that the effect 
of TNF-α may not be dose-dependent but a likely response of all or none pattern. On 
the other hand, TNF-α did not cause any notable change in MUC1, MUC4, and MUC16 
expression in the stratified human conjunctival epithelial cells (Fig. 2B).  
Consistent with the effects observed with IL-6 and TNF-α, IFN-γ exposure also 
caused a significant (p<0.05 compared to control cells not exposed to IFN-γ) increase in 
the gene expression of MUC1 and MUC4 in the stratified human corneal epithelial cells 
but did not cause any change in MUC16 gene expression (Fig. 3A). Just like TNF-α, 
various doses of IFN-γ also caused a similar increase in the gene expression of MUC1 
and MUC4, suggesting that the effect of IFN-γ are not dose-dependent but follow all or 
none response. On the contrary, Fig. 3B shows that IFN-γ did not cause any significant 
change in the gene expression of MUC1, MUC4, and MUC 16 in stratified human 
conjunctival epithelial cells. 
Effect of IL-6, TNF-α and IFN-γ on stratified human corneal and conjunctival 
epithelial cell glycocalyx 
 
The integrity of glycocalyx is important for the barrier, lubrication, and hydration 
functions of ocular surface epithelial cells [1,2]. Glycocalyx, along with mucins, contains 
side-chain structural and chemical components to form a network [1-7]. Proinflammatory 
cytokines have been shown to increase enzymes that can digest these components and 
damage glycocalyx [22,23]. Therefore, we next tested the effect of these 
proinflammatory cytokines on human corneal and conjunctival epithelial cell glycocalyx. 
Wheat germ agglutinin lectin binds to the sialic acid residues and has been previously 
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used to stain the glycocalyx [28,29]. Fig. 4 shows the top projection of 3-D confocal 
images of glycocalyx (stained green with wheat germ agglutinin) in stratified human 
corneal epithelial cells. As shown in Fig. 4, treatment of corneal epithelial cells with IL-6, 
TNF-α, and IFN-γ (250 pg/ml) did not cause any detrimental effect on corneal epithelial 
cells glycocalyx. Digital quantification of randomly captured images revealed an average 
stained area of 92 + 6% in control corneal epithelial cells, 93 + 8% in IL-6 treated 
corneal epithelial cells, 90 + 10 % in TNF-α treated corneal epithelial cells, and 92 + 9% 
in IFN-γ treated stratified human corneal epithelial cells.  
Fig. 5 shows the top projection of 3-D confocal images of glycocalyx (stained 
green with wheat germ agglutinin) in stratified human conjunctival epithelial cells.  As 
was seen with the corneal epithelial cells, treatment with IL-6, TNF-α, and IFN-γ (250 
pg/ml) did not cause any detrimental effect on conjunctival epithelial cells glycocalyx. 
Digital quantification of randomly captured images revealed an average stained area of 
80 + 11% in control corneal epithelial cells, 79 + 8% in IL-6 treated corneal epithelial 
cells, 81 + 10 % in TNF-α treated corneal epithelial cells, and 77 + 9% in IFN-γ treated 
conjunctival epithelial cells. 
Effect of IL-6, TNF-α and IFN-γ on stratified human corneal and conjunctival 
epithelial cell necrosis and apoptosis 
 
Loss of epithelial cell viability can compromise the ocular surface health and can 
perpetuate the inflammation. Therefore, we next tested the effect of IL-6, TNF-α, and 
IFN-γ on human corneal and conjunctival epithelial cell necrosis and apoptosis. None of 
the cytokines caused any significant increase in apoptotic cell death of human corneal 
epithelial cells (Fig. 6A). Interestingly, IL-6 treatment (250 pg/ml) caused a significant 
(p<0.05) increase in necrotic cell death (Fig. 6A). Like the effect observed in human 
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corneal epithelial cells, none of the tested cytokines caused any increase in apoptotic 
cell death of human conjunctival epithelial cells (Fig. 6B). In contrast to human corneal 
epithelial cells, TNF-α instead of IL-6 caused a significant (p<0.05) increase in the 
necrotic cell death of human conjunctival epithelial cells.  
Discussion 
Cytokines play an important role in the initiation and perpetuation of dry eye 
disease [10-14,30,31]. Exposing ocular surface epithelial cells to hyperosmolar stress 
causes the release of proinflammatory cytokines [15,16]. The level of these 
proinflammatory cytokines is also significantly increased in the tears of dry eye patients 
and the conjunctiva of dry eye patients with Sjogren’s syndrome [17,31,32]. Further, an 
inverse correlation has been demonstrated between the levels of these cytokines and 
the fluorescein staining and goblet cell density [32].  
The apical surface of corneal and conjunctival epithelial cells is covered with 
glycocalyx [1-7]. Membrane-tethered mucins are important components of glycocalyx 
[1-7]. Multiple studies have shown that proinflammatory cytokines can modulate the 
expression of membrane-tethered mucins in oral, nasal, and respiratory mucosal 
epithelium [33-36]. The results of this study demonstrate that IL-6, TNF-α, and IFN-γ 
increase the expression of MUC1 and MUC4 in the corneal epithelial cells at the 
picogram levels. Interestingly, our data demonstrate that these cytokines do not affect 
the MUC1 and MUC4 expression in conjunctival epithelial cells. Although both corneal 
and conjunctival epithelial cells are reported to express the receptors for these 
cytokines [37-39], the differential effect of these cytokines on MUC1 and MUC4 gene 
expression in corneal and conjunctival epithelial cells may be due to differences in the 
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receptor density, presence of decoy molecules, differential activation of signaling 
pathways, or different response of mucin promoters in the two epithelial cell types. 
Multiple studies have demonstrated that MUC1 has anti-inflammatory properties due to 
the negative regulation of Toll-like receptors [40,41]. Studies have also demonstrated 
that MUC1 can act as a microbial scavenger to limit Campylobacter jejuni and 
Helicobacter pylori infection in the gastrointestinal tract in a mouse model and limit S. 
pneumoniae infection in epithelial cells [42-44]. Therefore, the cytokine-mediated 
increase in gene expression of corneal epithelial MUC1 and MUC4 could possibly 
represent a physiological response to enhance the ocular surface defense against 
microbial stress. Interestingly, none of the three tested cytokines caused any notable 
change in the gene expression of MUC16 in both corneal as well as conjunctival 
epithelial cells, suggesting that the picogram dose of these cytokines is not sufficient to 
modulate MUC16 gene expression. 
Cytokines have also been shown to induce the expression of enzymes such as 
heparanase and hyaluronidase, which can damage the mucin side chains, thus 
compromising the integrity of glycocalyx [22,23]. TNF-α has been shown to induce 
endothelial glycocalyx shedding resulting in increased vascular permeability and 
aberrant vasodilation [45]. However, the results of the present study demonstrate that 
IL-6, TNF-α, and IFN-γ do not have any detrimental effect on corneal and conjunctival 
epithelial cell glycocalyx. Lastly, none of the cytokines caused an increase in apoptotic 
cell death, but an increase in necrotic cell death was noted with TNF-α in conjunctival 
epithelial cells and with IL-6 treatment in corneal epithelial cells.  
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In summary, the results of the present study demonstrate that IL-6, TNF-α, and 
IFN-γ have differential effects on corneal and conjunctival epithelial cells mucins gene 
expression and cause an increase in MUC1 and MUC4 gene expression only in corneal 
epithelial cells. Furthermore, these cytokines did not cause any notable change in the 
corneal and conjunctival glycocalyx and apoptotic cell death. 
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Fig. 1. Effect of IL-6 on MUC1, MUC4, MUC16 gene expression in stratified cultures of 
human corneal (A) and conjunctival (B) epithelial cells. The cells were exposed to IL6 
for 24 hours.  




Fig. 2. Effect of TNF-α on MUC1, MUC4, MUC16 gene expression in stratified cultures 
of human corneal (A) and conjunctival (B) epithelial cells. The cells were exposed to 
TNF-α for 24 hours.  





Fig. 3. Effect of IFN-γ on MUC1, MUC4, MUC16 gene expression in stratified cultures 
of human corneal (A) and conjunctival (B) epithelial cells. The cells were exposed to 
IFN-γ for 24 hours.  






Fig. 4. Representative confocal Z-stack images showing glycocalyx staining in stratified 
cultures of human corneal epithelial cells exposed to IL-6, TNF-α, and IFN-γ (250 pg/ml) 
for 24 hours. Nuclei are stained blue with DAPI and glycocalyx is stained green with 




Fig. 5. Representative confocal Z-stack images showing glycocalyx staining in stratified 
cultures of human conjunctival epithelial cells exposed to IL-6, TNF-α, and IFN-γ (250 
pg/ml) for 24 hours. Nuclei are stained blue with DAPI and glycocalyx is stained green 





Fig. 6. Flow cytometry quantification of apoptosis and necrosis in stratified human 
corneal (A) and conjunctival (B) epithelial cells treatment with IL-6, TNF-α, and IFN-γ 
(250 pg/ml) for 24 hours. The cells were stained with annexin V/propidium iodide dual 
staining for flow cytometry quantification.  
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Purpose: The present study was designed to investigate the role of myofibroblast 
transdifferentiation and conjunctival renin angiotensin system (RAS) in the pathogenesis 
of graft versus host (GVHD)-associated conjunctival fibrosis. 
Methods: A mouse model of major histocompatibility-matched allogeneic transplantation 
was used to induce GVHD with male B10.D2 mice as donors and BALB/c mice as 
recipients. Male BALB/c to female BALB/c syngeneic transplant was used as control. 
Chromosome Y staining in the spleen cells obtained from female recipient mice was 
used to confirm engraftment. Phenol red thread test and fluorescein staining were used 
to quantify tears and corneal keratopathy, respectively. The eye tissue was harvested at 
4 and 8 weeks after the transplant for immunostaining of smooth muscle actin, (α-SMA), 
a myofibroblast marker, angiotensinogen and angiotensin converting enzyme (ACE). 
Conjunctiva was harvested for RNA isolation, cDNA preparation and gene quantification 
of α-SMA, angiotensinogen and ACE using real time PCR.  
Results: More than 80% spleen cells in recipient mice were chromosome Y positive, 
thus conforming to successful engraftment. A significant decrease in tear secretion and 
a marked increase in corneal keratopathy score after allogeneic transplant indicated the 
onset of ocular GVHD in these mice. A significant increase in α-SMA gene expression 
and the presence of a large number of α-SMA positive cells was noted in the bulbar 
orbital conjunctiva of mice after allogeneic transplant. Allogenic transplant also caused a 
significant increase in the gene expression and protein expression angiotensinogen and 
ACE in the subconjunctival eyelid area. 
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Conclusion: Results of the present study demonstrate that GVHD-associated 
conjunctival fibrosis is accompanied by myofibroblast formation and activation of local 
tissue RAS. 
Introduction 
Allogeneic bone marrow transplantation is a standard treatment for many 
hematologic malignancies, hemoglobinopathies, and immunodeficiency diseases. 
However, graft versus host disease (GVHD) remains a challenging complication of 
allogeneic bone marrow transplantation. It is an immune-mediated condition that causes 
damage to many organs, including eyes, with 60%–90% of GVHD patients showing 
ocular complications (Kim, 2005; Nassiri et al, 2013). Eyes get affected in both acute 
and chronic GVHD, although ocular involvement is more common in patients with 
chronic GVHD. Acute GVHD can cause photophobia, hyperemia, conjunctivitis, 
lagophthalmos, and corneal ulceration (Franklin et al, 1986; Nassar et al, 2013; Nassiri 
et al, 2013; Qiu et al, 2018), whereas chronic GVHD is characterized by severe ocular 
surface damage resulting in dry eye, keratinization, epithelial thinning, squamous 
metaplasia, corneal ulceration and meibomian gland atrophy (Inamoto et al, 2019; 
Nassiri et al, 2013).  
Conjunctiva is also significantly affected in chronic GVHD patients with 
manifestations such as pseudomembranous conjunctivitis, symblepharon and fornix 
shortening (Nassar et al, 2013; Nassiri et al, 2013). Additionally, GVHD patients show a 
white scar under their bulbar conjunctiva suggestive of subepithelial conjunctival fibrosis 
(Kheirkhah et al, 2018; Kusne et al., 2017). Injury to conjunctival tissue caused by the 
chronic inflammatory response due to GVHD can initiate a wound healing response. 
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Excessive wound healing response may lead to aberrant extracellular matrix synthesis, 
thus resulting in conjunctival fibrosis. Myofibroblasts are contractile metabolically active 
cells that synthesis large quantities of extracellular matrix proteins and play a key role in 
fibrosis (Hinz et al, 2007; Klingberg et al, 2013; Wynn and Ramalingam, 2012). 
Myofibroblasts can form by trans-differentiation of a variety of cells such as resident 
fibroblasts, mesenchymal cells, and circulating fibrocytes (Hinz et al, 2007; Klingberg et 
al, 2013; Wynn and Ramalingam, 2012). Conjunctiva is a connective tissue containing a 
significant number of fibroblasts and presence of donor-origin fibrocytes has also been 
demonstrated in the eyes of GVHD patients (Ogawa et al., 2005).  
Conjunctival tissue has been shown to express components of local renin 
angiotensin system (RAS), including renin, angiotensinogen, angiotensin converting 
enzyme (ACE) and AT1 receptors (Holappa et al, 2017; Ramirez et al, 1996; Savaskan 
et al, 2004; Sramek et al, 1992; Wagner et al,1996). Like many other organs, role of 
angiotensin II, the end effector of RAS pathway, has been implicated in conjunctival 
fibrosis (Shi et al, 2015; Ye et al., 2020).  Components of RAS are upregulated after 
conjunctival injury (Shi et al, 2015). Angiotensin II has been shown to cause 
transdifferentiation of tenon’s fibroblasts to myofibroblasts (Ye et al., 2020). Profibrotic 
cytokines such as transforming growth factor beta (TGF-β), PDGF, CTGF released by 
immune cells in GVHD can serve as initial trigger for fibroblasts transdifferentiation to 
myofibroblasts (Dale and Saban, 2015; Ogawa et al., 2018). However, upregulation of 
RAS and a cross talk between profibrotic cytokines, especially TGF-β and RAS, can 
serve to amplify and perpetuate conjunctival fibrosis. The present study was designed 
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to investigate the role of myofibroblast transdifferentiation and conjunctival RAS in the 
pathogenesis of GVHD-associated conjunctival fibrosis. 
Materials and Methods 
Bone marrow transplantation  
 
The animal protocol was approved by the Institutional Animal Care and Use 
Committee of Chapman University. All animal experiments were conducted in 
accordance with the ARVO statements for eye research. Mouse model of major MHC 
match and minor MHC mismatch was used to induce GVHD. Male B10.D2 mice (The 
Jackson Laboratories, Bar Harbor, ME, USA) having a homozygous MHC haplotype d/d 
were used as donors and female BALB/c mice (The Chares River, Wilmington, MA, 
USA) also having a homozygous haplotype d/d were used as recipients. The control 
group was syngeneic transplantation, where donors were male BALB/c mice and 
recipient were female BALB/c mice. The femurs and spleen cells were harvested from 8 
weeks old donor mice, as described in our earlier publication (Shamloo et al., 2019). 
Recipient female BALB/c mice were exposed to 700 cGy irradiation using an X-Ray 
irradiator (RS 2000 X-ray Biological Irradiator, Rad Source Technologies, Buford, GA, 
USA). After 6 hours, the irradiated recipient female BALB/c mice were injected with 
2X106 spleen cells and 1X106 bone marrow cells. The mice were fed with diet gel 
(ClearH2O, Portland, ME, USA), housed in sterile cages, and received sulfatrim (0.672 
mg/mL) in their drinking water for two weeks after the transplant. At four and eight 
weeks after the transplantation, animals were euthanized by CO2 administration for the 
collection of ocular tissue. The study design included two different groups of mice: 1) 
Control group included BALB/c female mice (n=9) that received syngeneic bone marrow 
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and spleen cell transplantation from male BALB/c mice 2) Ocular GVHD group included 
female BALB/c mice (n =12) that received allogeneic bone marrow and spleen cell 
transplantation from male B10/D2 mice. 
Monitoring of engraftment 
 
The presence of chromosome Y in the spleen cells of female recipient mice was 
used to track engraftment by male donor marrow. A fluorescent paint probe was used to 
stain chromosome Y by fluorescent in situ hybridization using a commercially available 
kit (Empire genomics, Williamsville, NY). Mice were also monitored for systemic signs of 
chronic GVHD, such as loss of body weight and body hair. 
Tear quantification 
 
Tear secretion was quantified by phenol red thread (FCI Ophthalmics, Pembroke, 
MA, USA) which is pH sensitive and changes from yellow to red upon wetting by tears. 
The thread was placed in temporal side of lower eye lid for 1 minute and the length of 
color change was measured in millimeters and converted to volume using a standard 
plot. A standard curve was plotted by wetting the thread with known volume of artificial 
tears and measuring the length of the wetted phenol red thread. Due to the small 
amount of tear film volume in the mouse eyes, the phenol red thread test typically 
requires longer time to obtain consistent values, accordingly 1-minute duration for 
phenol red thread test was used. Tear volume was quantified before the allogeneic and 
syngeneic transplantation (baseline) and at week 2, 4, 6 and 8 after the transplantation 





Mice were anesthetized by intraperitoneal injection of ketamine (80 mg/kg) and 
xylazine (5 mg/kg). A 2-μL sterile solution of 0.5% fluorescein was applied to mouse eye 
and imaging was performed under cobalt filter with a slit lamp (SL-17, Kowa, USA) 
using a digital camera. The captured corneal images were divided into four hypothetical 
quadrants for scoring the keratopathy using a previously published method (Shamloo et 
al, 2019; Zhang et al, 2014). Each quadrant was scored as follows: no staining = 0; 
slightly punctate staining less than 30 spots = 1; punctate staining more than 30 spots, 
but not diffuse = 2; diffuse staining but no positive plaque = 3; positive fluorescein 
plaque = 4. The scores of each quadrant were added to arrive at a final grade (total 
maximum possible score =16).  
Tissue harvesting and cryosectioning 
 
Eyes along with the eyelids were harvested from euthanized animals. The tissue 
was fixed in 4% paraformaldehyde overnight followed by immersion in 15% and 30% 
sucrose, respectively. The tissue was embedded in optimal cutting temperature (OCT) 
using 2-methylbutane bath cooled over liquid nitrogen. The sagittal sections were cut 
from frozen tissue at 8-μm thickness using cryostat (CM 1860, Leica, Germany) for 
performing immunofluorescent staining.  
Immunofluorescence staining for α-SMA, angiotensinogen and ACE 
 
Slides containing 8 μm thick sagittal sections of eye and eyelid were rinsed in 
phosphate buffer saline (PBS) and blocked with PBS solution containing 2% bovine 
serum albumin for 30 min. The tissue sections were then incubated with primary 
antibodies for α-SMA (1:1,00 dilution, Invitrogen, Carlsbad, CA), angiotensinogen (1:50 
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dilution R&D systems, Minneapolis, MN) and ACE (1:25 dilution R&D systems, 
Minneapolis, MN) for 90 minutes. The slides were washed with PBS three times and 
incubated with Alexa 488- or Alexa 647-conjugated secondary antibody (1: 500 Dilution, 
Abcam, Cambridge, MA) for 60 minutes (Sharma et al., 2009; 2012). The nuclei were 
stained with DAPI. The slides were images using confocal microscope (Nikon, Melville, 
NY). The number of nuclei showing α-SMA staining and the percent fraction of area 
showing angiotensinogen and ACE staining was quantified using Image J.  
RNA isolation, cDNA preparation and gene expression quantification  
 
The whole sheet of bulbar conjunctival tissue was removed by using iris scissor 
and fine pointed forceps from euthanized animals’ eye at the end of 4 and 8 weeks after 
transplantation. The mRNA was extracted using the RNeasy Mini kit (RNeasy kit; 
Qiagen Inc., Valencia, CA). The mRNA was immediately reverse transcribed to 
complementary DNA (cDNA) using a commercially available kit (Superscript III First-
strand synthesis; Thermo Fisher Scientific). The cDNA was used to quantify α-SMA, 
angiotensinogen and ACE gene expressions using real-time PCR. A 20-μL reaction 
mixture containing 2 μL of cDNA, 2 μL each of 200 nM of forward primer and reverse 
primer (Table 1), and 10 μL of 23 SYBR green super mix was run at a universal cycle 
(95 ⁰C for 10 minutes, 40 cycles at 95 ⁰C for 15 seconds, and 550C for 60 seconds) in a 
thermocycler (Biorad CFX thermocycler; Bio-Rad Laboratories, Hercules, CA, USA). β-
actin was used as the housekeeping gene. The relative change in gene expression was 





Characterization of GVHD and allogenic transplantation 
 
Mice who received allogeneic transplantation started exhibiting signs of GVHD at 
around 4 weeks that included significantly lower body weight (Figure 1A), signs of skin 
scleroderma, and loss of body hair (Figure 1B). Interestingly, a sharp decrease in body 
weight was observed up to the initial 2 weeks after transplantation in both groups that 
received either allogeneic or syngeneic transplantation. This early decrease in body 
weight noted in both the groups can be likely attributed to the irradiation stress (Figure 1 
A). Both groups regained body weight by week 4. However, the regain of body weight 
was significantly lower in mice with allogeneic transplants compared to mice that 
received a syngeneic transplant. Furthermore, after this initial recovery, mice with 
allogeneic transplant did not show any further gain, and their body weight plateaued, 
suggesting the onset of systemic GVHD. On the other hand, mice that received 
syngeneic transplantation continued to show an upward trend with a notable increase in 
body weight (Figure 1A).  
Since the donor mice in our model were male while the recipient mice were 
female, we used Y chromosome staining to confirm the successful engraftment of donor 
origin marrow cells. Figure 1C shows fluorescent in-situ hybridization staining for 
chromosome Y in the spleen cells obtained from recipient female mice at 4 weeks after 
allogeneic transplant. Quantification of spleen cells from five different animals showed 
an average of 80% spleen cells showing chromosome Y staining, thus confirming the 
successful engraftment of recipient mice by cells originating from male donor marrow. 
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Clinical signs of ocular GVHD  
 
The mice who received allogeneic transplantation showed signs of ocular GVHD 
that included a decrease in tear film and onset of corneal keratopathy. Figure 2 shows 
time-dependent changes in tear film volume in mice that received syngeneic and 
allogeneic transplantation. Both groups had an average tear volume of 153nl and 137nl 
at the baseline prior to transplant. Just like body weight, both groups showed a 
decrease in tear film volume at 2 weeks after the transplant, which could be attributed to 
irradiation stress-related physiological changes. However, mice that received allogeneic 
transplants continued to show a further decline in tear film volume at weeks 6 and 8 
after the initial slight regain at week 4.  The tear volume in the mice with allogenic 
transplant was significantly less compared to mice that received a syngeneic transplant.  
Figure 3A shows a representative fluorescein-stained image of mice eyes that received 
syngeneic or allogeneic transplantation. The corneas of mice that received allogeneic 
transplant showed punctate staining at week 4 and even plaques after week 8. 
Quantification of corneal keratopathy showed that both groups had a mean score of 2 at 
the baseline (Figure 3B). Mice that received allogenic transplantation showed a 
significant increase in the corneal keratopathic score to 6 and 9.3 at 4 weeks and 8 
weeks, respectively. The syngeneic mice also showed a slight increase in keratopathy 
score to 3.6 at week 8, possibly due to aging (Figure 3B).  
Presence of conjunctival myofibroblasts in ocular GVHD  
 
The presence of myofibroblasts is a hallmark feature of fibrosis. Myofibroblasts 
express high levels of intracellular bundles of α-SMA. Therefore, to test whether ocular 
GVHD causes conjunctival fibrosis due to myofibroblast formation, we used gene 
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expression to quantify α-SMA and performed α-SMA immunostaining to detect the 
localization of myofibroblasts. A 2.7-fold (p<0.05) and 2.02-fold increase in α-SMA gene 
expression was observed in the conjunctival tissue obtained from mice at 4 weeks and 
8 weeks after allogeneic transplantation (Figure 4). Furthermore, immunostaining 
detected the presence of a large number of α-SMA positive myofibroblasts in bulbar 
orbital conjunctiva of mice at 4 and 8 weeks after an allogeneic transplant (Figure 5A). 
On the other hand, no myofibroblasts could be detected in the tissue sections obtained 
from mice that received a syngeneic transplant (Figure 5A). Quantification of the 
number of nuclei showed an average of 1079 α-SMA positive nuclei at 4 weeks and 978 
α-SMA positive nuclei at 8 weeks after allogeneic transplantation compared to around 
250 α-SMA positive nuclei in mice that received a syngeneic transplant (Figure 5B).  
Ocular GVHD and conjunctival RAS activation 
 
To test whether conjunctival fibrosis was accompanied by activation of local 
RAS, we quantified gene expression of angiotensinogen and ACE. We also detected 
angiotensinogen and ACE localization by performing immunostaining. A statistically 
significant 1.4-fold (p<0.05) increase in gene expression of angiotensinogen and a 2-
fold (p<0.05) increase in gene expression of ACE was observed in the conjunctival 
tissue obtained from mice at 4 weeks after allogeneic transplantation. By 8-week time 
point, this noted increase in angiotensinogen and ACE returned to the baseline (Figure 
6).  
Immunostaining detected a large area under the bulbar conjunctiva that was 
intensely stained for angiotensinogen (Figure 7A) and ACE (Figure 8A) at 4 weeks after 
allogeneic transplant. On the other hand, angiotensinogen and ACE staining was barely 
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detectable in the eyelids of mice that received syngeneic transplant. Quantification of 
the percentage of the stained area as fraction of total eyelid for angiotensinogen 
showed only 4% stained area in mice that received syngeneic transplant but 37% 
stained area (p<0.05) and 22% stained area (p<0.05) in mice at 4 weeks and 8 weeks 
after the allogeneic transplant, respectively (Figure 7B). Similarly, < 0.4% area showed 
ACE staining in mice that received syngeneic transplant compared to 2% (p<0.05) and 
1.5% area at 4 weeks and 8 weeks in mice that received allogeneic  transplantation 
(Figure 8B) 
Discussion 
Fibrosis is one of the key features of chronic GVHD affecting many organs, 
including lungs, skin, and GI tract (Ghimire et al., 2017; Kitko et al, 2012; Min, 2011; 
Zeiser and Blazar, 2017). Clinical subepithelial fibrosis appearing as a white scar has 
been reported in the eyelids of chronic GVHD patients (Kheirkhah et al, 2018; Kusne et 
al., 2017). Studies have also shown a correlation between conjunctival fibrosis and 
corneal epitheliopathy, suggesting that conjunctival fibrosis likely contributes to dry eye 
and ocular surface damage in GVHD (Kheirkhah et al, 2018; Kusne et al., 2017). The 
present study used B10D2 to BALB/c major MHC match and minor MHC mismatch 
mouse model to investigate whether this mouse model shows features of conjunctival 
fibrosis as characterized by the presence of myofibroblasts. This mouse model exhibits 
scleroderma-like features, as is also confirmed in the present study, and the model has 
been extensively used to study GVHD-associated fibrosis in various organs (Chu and 
Gress, 2008; McCormick et al., 1999; Yaguchi et al., 2013). The results of the present 
study demonstrate that this model indeed shows features of conjunctival fibrosis as 
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demonstrated by presence of myofibroblasts. Furthermore, the model recapitulates 
many other features of ocular GVHD, including dry eye and corneal keratopathy. 
Interestingly, conjunctival fibrosis was noted at 4 weeks without any further increase in 
severity at 8 weeks, whereas tear film and keratopathy score continued to decline up to 
the tested time point of 8 weeks. This trend tentatively suggests that the conjunctival 
fibrosis sets in early and may contribute to the ocular surface damage in this model as 
is observed in clinical studies. 
The repair process during fibrosis typically involves deposition of excessive 
extracellular matrix, which results in replacement of normal parenchymal tissue with the 
hypertrophic scar tissue. Myofibroblast formation and proliferation is a critical step in 
fibrosis (Hinz et al, 2007; Klingberg et al, 2013; Wynn and Ramalingam, 2012). 
Myofibroblasts are metabolically active cells, which synthesize and secrete large 
quantities of extracellular matrix during fibrosis (Hinz et al, 2007; Klingberg et al, 2013; 
Wynn and Ramalingam, 2012). Myofibroblasts also contribute to altered mechanical 
properties of the tissues because they express high amounts of contractile bundles of 
cytoskeletal protein, α-SMA. The present study demonstrates a large number of α-SMA 
positive myofibroblasts in the orbital bulbar conjunctiva, suggesting that GVHD-
associated conjunctival fibrosis is accompanied by myofibroblast formation. The noted 
increase of α-SMA gene expression at week 4 after transplantation followed by a 
decline at week 8, but a comparable number of α-SMA-stained cells suggest an initial 
proliferative phase of myofibroblast formation after allogeneic transplantation followed 
by stabilization phase. The resolution phase of fibrosis is typically characterized by a 
decline in the myofibroblast number due to apoptosis and other mechanisms. 
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Interestingly, results of the current study demonstrate that resolution of GVHD-
associated conjunctival fibrosis likely requires a longer duration since a significant 
number of myofibroblasts were still present in the conjunctiva of GVHD mice up to the 
tested time point of 8 weeks. Furthermore, a shortening of eyelid and fornix was also 
consistently observed in the eyes of GVHD mice at 8 weeks. Given the detection of 
large populations of myofibroblasts and their localization in bulbar orbital conjunctiva of 
GVHD mice, it is highly likely that the tissue contractile changes caused by these 
myofibroblasts may be contributing to the noted alteration in the eyelid and fornix 
architect of these GVHD mice.  
GVHD is an immune condition mediated by a complex interplay between donor 
immune cells and host tissue. Immune cells of donor origin have been shown to be 
present in the recipient conjunctival tissue (Tatematsu et al., 2012). These immune cells 
can release a variety of profibrotic cytokines such as TGF-β, PDGF, CTGF that can 
trigger fibroblast activation and their transdifferentiation to myofibroblasts (Mack, 2018 
Rockey et al., 2015; Smigiel et al., 2018; Weiskirchen et al., 2019; Wynn, 2008). 
Further, these immune cells and activated fibroblasts also secrete profibrotic vasoactive 
peptides such as endothelin and angiotensin that can perpetuate a vicious cycle of 
excessive wound healing and fibrosis (Mack, 2018; Rockey et al., 2015; Smigiel et al., 
2018; Weiskirchen et al., 2019; Wynn, 2008). Activation of RAS and elevated levels of 
its effector molecule ang II have been shown to play a critical role in mediating fibrosis 
in liver, skin, lungs, and cardiac tissue (Abdul-Hafez et al., 2018; Ferrario, 2016; Jia et 
al., 2018; Munshi et al., 2011; Wang et al., 2015). Ocular tissue has been shown to 
express all components of RAS (Holappa et al, 2017; Savaskan et al, 2004; Sramek et 
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al, 1992; Ramirez et al, 1996; Wagner et al,1996). Overaction of RAS has been shown 
to play a critical role in conjunctival fibrosis after trabeculectomy (Shi et al., 2015; Ye et 
al., 2020). Results of the present study demonstrate that GVHD-associated 
myofibroblast formation was accompanied by a significant increase in the gene and 
protein expression of angiotensinogen and angiotensin converting enzyme in the tissue 
around conjunctiva. Angiotensin II, directly or through increased levels of TGF-β, can 
promote fibroblast proliferation and myofibroblast differentiation. Therefore, the noted 
increase in local angiotensinogen and ACE activity observed in this study is likely to be 
an important contributor to the initiation and perpetuation of conjunctival fibrosis and 
myofibroblast formation. Overlapping temporal kinetics between the concomitant 
increase in angiotensinogen and ACE and an increase in SMA expression, as noted in 







Figure 1: Body weight of mice before (baseline) and at various time points after 
syngeneic and allogeneic transplantation (A). A significant (* p < 0.05) decrease in body 
weight was observed in mice who received an allogeneic transplant compared to mice 
with a syngeneic transplant. Representative photograph (B) showing signs of 
sclerodermatous skin lesions and hair loss in mice who received an allogeneic 
transplant. Spleen cells of recipient (female) mice showing Y chromosome staining 





Figure 2: Tear film volume in mice before (baseline) and at various time points after 
syngeneic and allogeneic transplantation. A significant (* p < 0.05) decrease in tear film 
volume was observed in mice who received an allogeneic transplant compared to mice 





Figure 3: Representative fluorescein-stained images of corneas at 8 weeks after 
syngeneic transplant (control) and at 4 weeks, 8 weeks after allogeneic transplant 
(GVHD). Quantification of fluorescein staining (B) showed significant (* p < 0.05) 
compared with syngeneic and before transplantation) corneal keratopathy at 4 and 8 






Figure 4: Gene expression quantification of α-smooth muscle actin in conjunctival 
homogenates obtained from mice at 8 weeks after syngeneic transplant (control) and at 
4 weeks, 8 weeks after allogeneic transplant (GVHD). A significant increase in α-smooth 
muscle actin gene expression was noted in conjunctival homogenates obtained from 
mice (*p<0.05) after allogeneic transplant compared to the tissues obtained from mice 





Figure 5: Representative confocal images (A) showing immunofluorescent staining 
(green) for α-smooth muscle actin in the eyelid tissue sections obtained from mice at 8 
weeks after syngeneic transplant (control) and at 4 weeks, 8 weeks after an allogeneic 
transplant (GVHD). Nuclei are stained blue with DAPI. Graph (B) shows quantification of 
α-smooth muscle actin-stained nuclei in images obtained from 5 different slides, each 
from n=5 mice. A significant increase (* p<0.05) in α-smooth muscle actin-stained nuclei 
was observed in tissues obtained from mice at 4 weeks and 8 weeks after allogeneic 




Figure 6: Gene expression quantification of angiotensinogen and angiotensin 
converting enzyme in conjunctival homogenates obtained from mice at 8 weeks after 
syngeneic transplant (control) and at 4 weeks, 8 weeks after allogeneic transplant 
(GVHD). A significant increase in angiotensinogen and angiotensin converting enzyme 
gene expression was noted in conjunctival homogenates obtained from mice (*p<0.05) 







Figure 7: Representative confocal images (A) showing immunofluorescent staining 
(green) for angiotensinogen in the eyelid tissue sections obtained from mice at 8 weeks 
after syngeneic transplant (control) and at 4 weeks, 8 weeks after an allogeneic 
transplant (GVHD). Nuclei are stained blue with DAPI. Graph (B) shows quantification of 
angiotensinogen-stained area (calculated as a fraction of total eyelid area) using images 
obtained from 5 different slides each from n=5 mice. A significant increase (* p<0.05) in 
angiotensinogen-stained area was observed in tissues obtained from mice at 4 weeks 
and 8 weeks after allogeneic transplant compared to the tissues obtained from mice that 
received a syngeneic transplant. 
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Figure 8: Representative confocal images (A) showing immunofluorescent staining 
(red) for angiotensin converting enzyme in the eyelid tissue sections obtained from mice 
at 8 weeks after syngeneic transplant (control) and at 4 weeks, 8 weeks after allogeneic 
transplant (GVHD). Nuclei are stained blue with DAPI. Graph (B) shows quantification of 
angiotensinogen-stained area (calculated as a fraction of total eyelid area) using images 
obtained from 5 different slides each from n=5 mice. An increase in angiotensin 
converting enzyme-stained area was observed in tissues obtained from mice at 4 weeks 
(* p<0.05) and 8 weeks after allogeneic transplant compared to the tissues obtained 
from mice that received syngeneic transplant. 
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Reverse Primer Forward Primer 
Angiotensinogen 5’CAA GTT GAT CTT CCA CCC TGT C3’ 5’TCC CAC GCT CTC TGG ATT TA3’ 
ACE 5’TTG CTG CCC TCT ATG GTA ATG3’ 5’GAC AGG TTC GTG GAA GAG TAT G3’ 
SMA 5’GGC AGT AGT CAC GAA GGA ATA G3’ 5’CCA TCA TGC GTC TGG ACT T3’ 
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Discussion, Conclusion and Future Direction 
 
GVHD is a significant complication after stem cell transplantation that happens 
due to abnormal immune response to the healthy host tissue. It can cause damage to 
vital organs, including the eye and results in dry eye disease 1-5. 
Dry eye is a multifactorial disease of the ocular surface characterized by loss of 
tear film homeostasis characterized by tear film instability, hyperosmolarity, ocular 
surface inflammation, and neurosensory abnormalities6. Tear film is composed of three 
layers. Outer lipid layer which is produced by the meibomian gland, and it covers the 
tear surface to prevent tear film evaporation. The middle aqueous layer produced by 
lacrimal gland, lubricates the eye surface and provides oxygen and nutrients to the 
cornea. Inner mucin layer retains tear to the eye surface, repels microbes and lubricates 
the eye surface 7. Hemostasis of these three layers maintains the ocular surface's 
health, and damage to any aspect of these components leads to dry eye disease 6,8.  
The pathogenesis of GVHD-associated dry eye is incompletely understood. 
Previous studies have shown that GVHD causes fibrosis of lacrimal glands, which could 
potentially lead to reduced aqueous layer, thus resulting in ocular surface dryness 9,10. 
However, the lipid and mucin layer's role have not been studied in GVHD-associated 
dry eye disease. Studies in Sjögren and non-Sjögren related dry eye disease 
demonstrated a decrease in ocular surface mucins and glycocalyx barrier 10,11. Another 
study among contact lens wearers showed that solutions containing purified gastric 
mucins could help relief against dry eye 12. However, the effect of GVHD on ocular 
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surface mucins is not studied yet; therefore, we decided to investigate ocular surface 
mucins' role in GVHD-associated dry eye disease. Our GVHD mouse model 
demonstrated clinical signs of dry eye disease, as was evident from the decreased tear 
film and the presence of keratopathies. In this work, for the first time, we demonstrate 
that GVHD causes damage to the ocular surface glycocalyx and causes alteration of 
ocular surface mucins. Our results are in agreement with previous observations of 
decreased mucins in Sjögren disease-related dry eye disease13,14. In vivo administration 
of rebamipide has been demonstrated to have a beneficial effect on Sjogren’s syndrome 
by increasing glycocalyx barrier14. In this study, we tested the effect of rebamipide, a 
mucin secretagogue, on the GVHD-associated dry eye mouse model, which provided a 
significant protection against GVHD-associated dry eye by the maintaining of tear film 
secretion and a notable decrease in corneal keratopathy score. Although in this study, 
we investigated the effect of GVHD on specific mucins, but we did not investigate 
rebamipide's effect in the alteration of specific ocular surface mucins. Previous studies 
on stratified human cultured corneal epithelial cells, which were treated by rebamipide, 
have demonstrated an increase of mucin1615. These findings indicated that rebamipide 
might repair glycocalyx barrier disruption in dry eye disease as was noted in our data, 
through MUC16 protein expression. 
Multiple possible mechanism can contribute to the decrease in mucins and 
damage to glycocalyx that we noted in our first study. Conjunctiva forms a large part of 
ocular surface, contains goblet cells and contributes to both secreted and membrane-
tethered ocular surface mucins. Multiorgan fibrosis is a well-known complication in 
patients with chronic GVHD (cGVHD). While skin, liver, and gastrointestinal involvement 
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are the most common manifestations of acute GVHD, cGVHD may affect any organ, 
including lungs, skin, and eyes 16-18. Scleroderma-like changes and bronchiolitis 
obliterans syndrome are two of the most damaging outcomes in these patients, which 
were reported in 5 to 15 percent of patients with cGVHD 19. Ocular involvement in 
cGVHD is also very common and appears as severe ocular surface damage causing 
dry eye, keratinization, epithelial thinning, squamous metaplasia, corneal ulceration and 
meibomian gland atrophy 4,5,20. cGVHD has already been shown to cause an 
inflammatory destruction of the lacrimal glands with fibrosis, which decreases tear 
production, increases tear film osmalarity, and leads to dry eye disease 9,10. Conjunctiva 
is also significantly affected in chronic GVHD patients with pseudomembranous 
conjunctivitis, symblepharon, and fornix shortening manifestations 5,21. Clinical reports 
recently demonstrated that GVHD patients show a white scar under their bulbar 
conjunctiva which could be indicative of subepithelial conjunctival fibrosis 22,23. These 
subepithelial fibrotic changes in conjunctiva, as a goblet cell host, most possibly can 
decrease goblet cell density and ocular surface mucin production, and increase tear 
evaporation and result in dry eye disease. Our data for the first time demonstrated in a 
mouse model of cGVHD that cGVHD causes conjunctival fibrosis and it is accompanied 
by the presence of myofibroblasts in orbital conjunctival tissue and in Tenon’s capsule. 
Our data support the clinical reports of white eyelid scarring in GVHD patients that are 
indirectly suggestive of subconjunctival fibrosis in human GVHD. Furthermore, our 
mouse model of GVHD recapitulates many other features of ocular GVHD 
manifestations, including dry eye and corneal keratopathy.  
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Conjunctiva has local renin angiotensin system (RAS) including renin, 
angiotensinogen, angiotensin-converting enzyme (ACE), and AT1 receptors 24-28. A 
recent study show that components of RAS are upregulated after conjunctival injury 29 
and angiotensin treatment of conjunctival fibroblasts causes their transdifferentiation to 
myofibroblasts 30. Like many other organs, we think that angiotensin II, the end effector 
of RAS pathway, could play a role in conjunctival fibrosis. Angiotensin II could also 
potentiate the profibrotic effect of cytokines released by immune cells in GVHD 
especially TGF-β1 to transdifferentiate the conjunctival fibroblasts to myofibroblasts. 
Our data in mouse model of GVHD demonstrates that conjunctival fibrosis and 
myofibroblast formation is accompanied an increase in local angiotensinogen and ACE 
levels. Our data support the previous studies that angiotensin II type 1 receptor 
antagonist attenuate lung, and liver fibrosis in a murine model of chronic graft-versus-
host disease31.  
It is well known that osmotic stress is an important mechanism of ocular surface 
damages in dry eye. Studies have demonstrated that NFAT5 is a fundamental regulator 
of the osmotic stress in mammalian cells activated by hyperosmolar stress and had a 
detrimental effect in the induction of proinflammatory cytokines and stress-induced 
apoptosis in human limbal epithelial cells 32,33. GVHD-mediated damage to ocular 
mucins, glycocalyx and conjunctival fibrosis with a resultant increase in tear film 
evaporation will also potentially increase the tear osmolarity. Many clinical studies have 
reported an increase in tear osmolarity in GVHD patients 31-35. Hyperosmolarity has 
been shown to increase the release of proinflammatory cytokines from epithelial cells 36. 
Our study also demonstrated that corneal and conjunctival epithelial cells exposure to 
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hyperosmolar stress causes an increase in the gene expression of NFAT5 and 
cytokines IL-1, IL-6, TNF-α and IFN-γ. Next, we hypothesized that these 
proinflammatory cytokines can cause potentially cause a decrease in ocular mucins 
expression or can cause damage to glycocalyx as was noted in our fits study. But our 
data showed that these cytokines do not cause a decrease in ocular surface mucins but 
rather increase their levels or do not cause any damage to glycocalyx. A handful of 
studies have shown that proinflammatory cytokines can upregulate mucin gene 
expression in chronic inflammatory lung disease and intestinal cancer37-39. Studies have 
also reported that MUC1 can act as a microbial scavenger to inhibit bacterial infection in 
the gastrointestinal tract in a mouse model and in epithelial cells40-42. Therefore, the 
cytokine-mediated increase in gene expression of corneal epithelial MUC1 and MUC4 in 
our study could be a response to enhance the ocular surface defense against microbial 
stress that can increase cytokine levels. However, there has not been a study about the 
role of cytokine mediated changes in mucin expression in the ocular surface epithelium 
and our is the first study. 
In summary, we investigated the effect of GVHD on tear film volume, corneal 
keratopathy, ocular surface glycocalyx, goblet cells, ocular surface mucins, and fibrosis 
of conjunctiva. We further studied whether hyperosmolar stress can modulate the 
release of pro-inflammatory cytokines from the ocular surface epithelial cells and if 
these pro-inflammatory cytokines can cause any detrimental changes to ocular surface 
glycocalyx and mucins. In Chapter 2, our data demonstrated that ocular GVHD-
associated dry eye is characterized by a significant decrease in tear film volume and the 
onset of corneal keratopathy. Ocular GVHD caused a significant decrease in the area 
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and thickness of corneal glycocalyx. A significant decrease in the goblet cells, mucin 4, 
and mucin 5AC levels were also observed. Topical treatment with rebamipide, a mucin 
secretagogue, partially attenuated ocular GVHD-mediated decrease in tear film volume 
and significantly reduced corneal keratopathy severity. In summary, our data 
demonstrated that ocular GVHD has a detrimental impact on ocular surface glycocalyx, 
and mucins and augmentation of ocular surface mucins is a viable pharmacological 
approach to partially prevent ocular GVHD-associated decrease in the tear film and the 
severity of corneal keratopathy.  
An Increase in tear osmolarity is a cardinal feature of dry eye disease. Osmotic 
stress activates stress-related kinases, and these kinases are responsible for increased 
transcription of the proinflammatory cytokines. In Chapter 3, we tested the effect of 
hyperosmolar stress on the changes in gene expression of NFAT5, a tonicity-regulated 
transcription factor and pro-inflammatory cytokines IL-1, IL-6, TNF- α, and IFN-γ using 
telomerase-immortalized human corneal and conjunctival epithelial cells. Our data 
demonstrated that hyperosmolar stress causes a remarkable increase in NFAT5 and 
proinflammatory cytokine gene expression in ocular surface epithelial cells. Human 
conjunctival and corneal epithelial cells showed a differential response to the 
hyperosmotic stress-mediated change in NFAT 5 and proinflammatory cytokines' gene 
expression, with human corneal epithelial cells being more sensitive to the 
hyperosmotic stress. The release of proinflammatory cytokines orchestrates the 
initiation and perpetuation of ocular surface inflammation. Cytokines IL-1, IL-6, TNF-α, 
and IFN-γ have been shown to participate in the early-stage and amplification-stage of 
dry eye disease. The levels of IL-6, TNF-α, and IFN-γ are known to be elevated in 
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patients suffering from dry eye disease. In Chapter 4, we tested the effect of picogram 
concentration of proinflammatory cytokines IL-6, TNF-α, and IFN-γ on the gene 
expression of membrane-tethered mucins MUC1, MUC4, MUC16, ocular surface 
glycocalyx, and viability of stratified cultures of telomerase-immortalized human corneal 
and conjunctival epithelial cells. Our data demonstrated that treatment with IL-6, TNF-α, 
and IFN-γ resulted in a significant increase in the gene expression of MUC1 and MUC4 
in stratified human corneal epithelial cells but did not cause a significant change in the 
gene expression of MUC16. Unlike corneal epithelial cells, these cytokines caused no 
significant changes in the expression of the MUC1, MUC4, and MUC16 genes in the 
stratified human conjunctival epithelial cells. Further, IL-6, TNF-α, and IFN-γ exposure 
did not cause any notable change in the stained area of glycocalyx in the stratified 
human corneal and conjunctival epithelial cells. None of the tested cytokines caused 
any significant increase in apoptotic cell death in stratified human corneal and 
conjunctival epithelial cells. However, treatment with IL-6 resulted in an increase in 
necrotic cell death in stratified human corneal epithelial cells. In contrast, TNF- α caused 
a significant increase in necrotic cell death of stratified human conjunctival epithelial 
cells.  
Finally, In Chapter 5, we investigated the role of myofibroblast transdifferentiation 
and conjunctival renin-angiotensin system (RAS) in graft versus host (GVHD) 
pathogenesis-associated conjunctival fibrosis. Our results demonstrated that ocular 
GVHD causes a significant increase in α-SMA gene expression and formation of 
myofibroblasts as demonstrated by the presence of α-SMA positive cells in the bulbar 
orbital conjunctiva of mice after allogeneic transplant. Ocular GVHD-associated fibrosis 
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also accompanies by a concomitant increase in the gene expression and protein 
expression of angiotensinogen and ACE in the subconjunctival eyelid area. 
Future Directions 
Future studies are needed to understand the mechanism of GVHD-mediated damage to 
ocular surface mucins and glycocalyx besides conjunctival fibrosis as shown in our 
study. Infiltration of ocular surface by donor T cells and T cell-mediated direct damage 
to corneal and conjunctival epithelial cells could be one such potential mechanism. The 
role of other immune cells including antigen presenting cells, and T regulatory cells and 
their interaction with ocular surface epithelial cells also needs to be investigated. Lastly, 
these immune cells especially macrophages can cause release of profibrotic cytokines 
such TGF-β and PDGF. The profibrotic cytokines can cause activation of other 
profibrotic pathways such as renin angiotensin system and transdifferentiation of 
fibroblasts to myofibroblasts resulting in ocular fibrosis as was observed in the present 
study. Polarization of macrophages from classically activated proinflammatory type to 
alternatively activated profibrotic healing type could be a transition in ocular GVHD from 
inflammatory to fibrotic phase. Future studies need to address whether GVHD causes 
donor macrophage infiltration into host cornea and conjunctiva and whether these 
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